Viral infectious disease
MONDO:0005108Any disease caused by a virus.
Also known as: Viruses caused disease or disorder, Viruses disease or disorder, Viruses infection, Viruses infectious disease, infection, viral, viral disease, viral disorder, viral infection
4637 clinical trials for this condition and its sub-types, 138 tagged with Viral infectious disease itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Viral infectious disease
-
Primary viral infectious disease 0 trials · 4,432 incl. sub-types
32 sub-types
- Viral sexually transmitted disease 5 trials · 1,654 incl. sub-types Sub-types →
- Lentivirus infection 2 trials · 1,629 incl. sub-types Sub-types →
- Nidovirales infectious disease 8 trials · 1,042 incl. sub-types Sub-types →
- Viral hepatitis 12 trials · 472 incl. sub-types Sub-types →
- Influenza 357 trials · 368 incl. sub-types Sub-types →
- Herpesviridae infectious disease 7 trials · 316 incl. sub-types Sub-types →
- Human papilloma virus infection 305 trials · 311 incl. sub-types Sub-types →
- Hepadnaviridae infectious disease 0 trials · 292 incl. sub-types Sub-types →
- Mononegavirales infectious disease 0 trials · 226 incl. sub-types Sub-types →
- Flaviviridae infectious disease 1 trial · 101 incl. sub-types Sub-types →
- Picornaviridae infectious disease 0 trials · 57 incl. sub-types Sub-types →
- Adenoviridae infectious disease 45 trials · 46 incl. sub-types Sub-types →
- Monkeypox 41 trials
- Bunyaviridae infectious disease 1 trial · 40 incl. sub-types Sub-types →
- Togaviridae infectious disease 0 trials · 33 incl. sub-types Sub-types →
- Deltaretrovirus infections 1 trial · 33 incl. sub-types Sub-types →
- Viral pneumonia 27 trials Sub-types →
- Viral encephalitis 3 trials · 17 incl. sub-types Sub-types →
- Smallpox 16 trials Sub-types →
- Rotavirus infection 12 trials
- Caliciviridae infectious disease 7 trials · 11 incl. sub-types Sub-types →
- Plantar wart 11 trials
- Arenaviridae infectious disease 1 trial · 9 incl. sub-types Sub-types →
- Rubella 9 trials Sub-types →
- Polyomavirus infectious disease 6 trials
- Viral exanthem 0 trials · 3 incl. sub-types Sub-types →
- Viral myocarditis 2 trials
- Cowpox 1 trial
- Astroviridae infectious disease 0 trials
- Aleutian mink disease, human 0 trials
- Phlebotomus fever 0 trials
- Viral pericarditis 0 trials
-
Viral respiratory tract infection 49 trials · 600 incl. sub-types
6 sub-types
- Influenza 357 trials · 368 incl. sub-types Sub-types →
- Respiratory syncytial virus infectious disease 176 trials · 178 incl. sub-types Sub-types →
- Common cold 39 trials
- Viral pneumonia 27 trials Sub-types →
- Hantavirus pulmonary syndrome 2 trials
- Viral laryngitis 0 trials
-
Coronavinae infectious disease 138 trials
-
Disease arising from reactivation of latent virus 4 trials · 97 incl. sub-types
3 sub-types
- Herpes zoster 81 trials Sub-types →
- Genital herpes 8 trials Sub-types →
- Herpes labialis 5 trials Sub-types →
-
Viral infection of central nervous system 3 trials · 59 incl. sub-types
7 sub-types
- Poliomyelitis 29 trials · 40 incl. sub-types Sub-types →
- Viral encephalitis 3 trials · 17 incl. sub-types Sub-types →
- Venezuelan equine encephalitis 1 trial
- Lymphocytic choriomeningitis 1 trial
- Central nervous system AIDS arteritis 0 trials
- Geniculate herpes zoster 0 trials
- Meningitis caused by poliovirus 0 trials
-
Viral hemorrhagic fever 12 trials · 54 incl. sub-types
16 sub-types
- Ebola hemorrhagic fever 22 trials
- Dengue hemorrhagic fever 7 trials Sub-types →
- Arenavirus hemorrhagic fever 0 trials · 7 incl. sub-types Sub-types →
- Crimean-Congo hemorrhagic fever 5 trials
- Marburg hemorrhagic fever 4 trials
- Rift valley fever 4 trials
- Hantavirus pulmonary syndrome 2 trials
- Venezuelan equine encephalitis 1 trial
- Hemorrhagic fever-renal syndrome 1 trial
- Bolivian hemorrhagic fever 0 trials
- Brazilian hemorrhagic fever 0 trials
- Chapare hemorrhagic fever 0 trials
- Kyasanur forest disease 0 trials Sub-types →
- Lujo hemorrhagic fever 0 trials
- Omsk hemorrhagic fever 0 trials
- Venezuelan hemorrhagic fever 0 trials
-
Arbovirus fever 0 trials · 47 incl. sub-types
2 sub-types
- Chikungunya 32 trials
- Yellow fever 16 trials
-
Kaposi's sarcoma 45 trials
4 sub-types
- Classic Kaposi sarcoma 3 trials
- Endemic Kaposi sarcoma 1 trial
- Iatrogenic Kaposi's sarcoma 1 trial
- Colorectal Kaposi sarcoma 0 trials Sub-types →
-
Human T-lymphotropic virus 1 infectious disease 5 trials · 36 incl. sub-types
2 sub-types
- Adult T-cell leukemia/lymphoma 32 trials
- Tropical spastic paraparesis 4 trials
-
Rabies 28 trials
-
Common wart 27 trials
-
Vaccinia 17 trials
-
Immunodeficiency 32B 9 trials
-
Arbovirus infection 8 trials
-
Viral eye infection 0 trials · 8 incl. sub-types
5 sub-types
- Herpes simplex virus keratitis 1 trial · 4 incl. sub-types Sub-types →
- Cytomegalovirus retinitis 2 trials
- Viral conjunctivitis 1 trial · 2 incl. sub-types Sub-types →
- Herpes zoster with dermatitis of eyelid 0 trials
- Infectious epithelial keratitis 0 trials
-
Human infection by orthopoxvirus 6 trials
-
Herpangina 3 trials
-
Milker's nodule 3 trials
-
Zika virus congenital syndrome 2 trials
-
Parvoviridae infectious disease 1 trial
2 sub-types
- Aleutian mink disease, human 0 trials
- Fetal parvovirus syndrome 0 trials
-
Molluscum contagiosum 1 trial
-
Pharyngoconjunctival fever 1 trial
-
Newcastle disease 0 trials
-
Reoviridae infectious disease 0 trials
-
Whitewater Arroyo hemorrhagic fever 0 trials
-
Congenital varicella syndrome 0 trials
-
Contagious pustular dermatitis 0 trials
-
Epidemic pleurodynia 0 trials
-
Exanthema subitum 0 trials
-
Focal epithelial hyperplasia 0 trials
-
Lumpy skin disease 0 trials
-
Neurolymphomatosis 0 trials
-
Pseudorabies 0 trials
-
Viral esophagitis 0 trials
-
Viral gastritis 0 trials
1 sub-type
- Herpetic gastritis 0 trials
-
Viral labyrinthitis 0 trials
-
Viral myositis 0 trials
Most studied deeper sub-types
Showing the 400 most recently updated of 1224 trials in this tab.
-
Can immune checkpoint inhibitors crack hepatitis B's functional cure?
Cure Recruiting nowResearchers are testing a new combination therapy for chronic hepatitis B that pairs immune checkpoint inhibitors (sintilimab or envafolimab) with interferon and a standard antiviral drug (entecavir, tenofovir, or tenofovir alafenamide). The goal is to see if this approach can he…
Phase 2 • Sponsor: The Second Affiliated Hospital of Chongqing Medical University • Aim: Cure
Last updated Oct 03, 2026 00:00 UTC
-
Can checkpoint inhibitors help the immune system clear hepatitis b?
Cure Recruiting nowResearchers are testing a combination of an anti-PD-1/anti-PD-L1 antibody, pegylated interferon alfa, and nucleos(t)ide analogues in adults with chronic hepatitis B. The goal is to see whether this mix can help more people lose hepatitis B surface antigen, which doctors call a fu…
Phase 2 • Sponsor: The Second Affiliated Hospital of Chongqing Medical University • Aim: Cure
Last updated Sep 30, 2026 00:00 UTC
-
Banked t cells target four viruses at once in children after transplant
Cure Expanded accessThis expanded access program lets doctors in Texas give banked, partially matched virus-specific T cells to children under 18 who have persistent or recurring EBV, CMV, adenovirus, or BK virus infections after an allogeneic stem cell transplant or CAR T therapy. The cells come fr…
Sponsor: Baylor College of Medicine • Aim: Cure
Last updated Sep 17, 2026 00:00 UTC
-
Hepatitis b cure breakthrough? new combo aims for 50%+ cure rate
Cure Recruiting nowThis study tests a new two-drug combination (ASC22 and Peg-IFNa) to see if it can functionally cure chronic hepatitis B. About 150 adults with low virus levels will receive the treatment. The goal is to raise the cure rate above 50% without needing lifelong medication.
Phase 4 • Sponsor: The Second Affiliated Hospital of Chongqing Medical University • Aim: Cure
Last updated Sep 03, 2026 00:00 UTC
-
Can hepatitis c be cured in just 4 weeks? a new trial puts it to the test
Cure Recruiting nowThis pilot study is testing whether a 4-week course of two antiviral drugs—sofosbuvir plus glecaprevir/pibrentasvir—can cure chronic hepatitis C in people who have not been treated before and have only mild liver scarring. Participants who relapse after the short treatment will r…
Phase 4 • Sponsor: Kirby Institute • Aim: Cure
Last updated Jul 31, 2026 00:00 UTC
-
New model aims to cure hepatitis c in homeless drug users
Cure Recruiting nowThis study tests a collaborative care model where pharmacists, doctors, and patient navigators work together to provide hepatitis C treatment to people who use drugs and live in supportive housing. 444 participants will be randomly assigned to either this model or usual care. The…
Sponsor: University of Washington • Aim: Cure
Last updated Jun 27, 2026 14:02 UTC
-
One shot, two viruses: vaccine aims to shield older adults from RSV and HMPV
Vaccine Recruiting nowResearchers are testing a single injection vaccine designed to protect adults 60 and older from two respiratory viruses: RSV and HMPV. The trial plans to enroll about 8,000 participants who will randomly receive either the vaccine or a placebo. Scientists will track who develops …
Phase 2 • Sponsor: Sanofi • Aim: Vaccine
Last updated Oct 20, 2026 06:00 UTC
-
New universal flu vaccine enters human testing
Vaccine Recruiting nowThis study tests an experimental flu vaccine called BPL-1357, given as a shot or nasal spray, to see if it is safe and can protect against multiple flu types. About 129 healthy adults aged 18-55 will receive the vaccine or a placebo, then be exposed to a flu virus in a controlled…
Phase 2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Vaccine
Last updated Oct 20, 2026 06:00 UTC
-
New nasal spray COVID booster enters human testing
Vaccine Recruiting nowThis early-stage trial is testing a new COVID-19 booster vaccine called OCU500, which is given as a nasal spray or inhaled mist instead of a shot. The study involves 80 healthy adults aged 18-64 who have already been vaccinated against COVID-19. Researchers are checking if the va…
Phase 1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Vaccine
Last updated Oct 18, 2026 00:00 UTC
-
Can a booster RSV shot shield the immunocompromised?
Vaccine Recruiting nowThis phase 3 trial is investigating whether giving a repeat dose of the RSVpreF vaccine to immunocompromised adults is safe and triggers a strong immune response. Participants, aged 18 and older, will receive one shot and be monitored for about a year. The study aims to find the …
Phase 3 • Sponsor: Pfizer • Aim: Vaccine
Last updated Oct 16, 2026 00:00 UTC
-
One shot, two viruses: could a combined vaccine shield seniors from RSV and HMPV?
Vaccine Recruiting nowThis trial is testing an experimental vaccine designed to protect against two respiratory viruses at once: RSV and HMPV. The study involves about 2,400 adults aged 60 and older, who will receive one of several dose levels of the vaccine, a placebo, or a control vaccine. Researche…
Phase 1/2 • Sponsor: Sanofi • Aim: Vaccine
Last updated Oct 16, 2026 00:00 UTC
-
RNA vaccine aims to control HIV without daily pills
Vaccine Recruiting nowThis study tests an experimental RNA-based vaccine called BNT168 in adults both with and without HIV. The goal is to see if the vaccine is safe, triggers an immune response, and can help control the amount of virus in the body. Participants receive either the vaccine or a placebo…
Phase 1 • Sponsor: BioNTech SE • Aim: Vaccine
Last updated Oct 16, 2026 00:00 UTC
-
New yellow fever vaccine trial for kids could boost global protection
Vaccine Recruiting nowThis Phase 3 trial tests a new yellow fever vaccine (vYF) in about 2,440 healthy children aged 9 months to 5 years. Researchers will compare vYF to two licensed vaccines (Stamaril and YF-VAX) to see if it triggers a strong immune response and is safe. Some children will also rece…
Phase 3 • Sponsor: Sanofi • Aim: Vaccine
Last updated Oct 16, 2026 00:00 UTC
-
Lassa fever vaccine candidate put to the test
Vaccine Recruiting nowLassa fever is a severe viral illness common in West Africa, and no effective treatment exists. Researchers are testing a new vaccine candidate called MOPEVAC-Las in 72 healthy adults aged 18 to 55. The trial compares three different doses of the vaccine to a placebo, given as tw…
Phase 1 • Sponsor: Institut Pasteur • Aim: Vaccine
Last updated Oct 15, 2026 00:00 UTC
-
MRNA flu shot put to the test in 3,000 adults
Vaccine Recruiting nowResearchers are testing an mRNA-based seasonal influenza vaccine in adults aged 18 to 64. The trial compares the immune response and side effects of the mRNA vaccine against standard flu vaccines. About 3,000 participants receive one injection in the upper arm and are followed fo…
Phase 3 • Sponsor: GlaxoSmithKline • Aim: Vaccine
Last updated Oct 11, 2026 00:00 UTC
-
Can a nanoparticle vaccine train the body to fight HIV?
Vaccine Recruiting nowThis early-stage trial is testing whether experimental HIV vaccines can safely teach the immune system to recognize and fight the virus. Healthy adults without HIV will receive a protein nanoparticle vaccine, followed by a booster—either another protein nanoparticle or an mRNA va…
Phase 1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Vaccine
Last updated Oct 11, 2026 00:00 UTC
-
New nasal vaccine aims to protect kids from RSV
Vaccine Recruiting nowThis study tests a new nasal spray vaccine (BLB-201) to prevent RSV, a common virus that can cause serious breathing problems in young children. About 137 infants and children aged 8 to 59 months will receive either the vaccine or a placebo. The goal is to check if the vaccine is…
Phase 1/2 • Sponsor: Blue Lake Biotechnology Inc. • Aim: Vaccine
Last updated Oct 11, 2026 00:00 UTC
-
Pfizer tests RSV vaccine aimed at older adults
Vaccine Recruiting nowResearchers are testing an RSV vaccine in healthy adults aged 60 and older to see how safe it is and how well it triggers an immune response. The trial enrolls about 600 people in China and the United States. In China, participants receive either the vaccine or a placebo; in the …
Phase 3 • Sponsor: Pfizer • Aim: Vaccine
Last updated Oct 11, 2026 00:00 UTC
-
Can shingrix shield HIV patients from shingles?
Vaccine Recruiting nowThis study tests the Shingrix vaccine in people with HIV and healthy volunteers to see how well it boosts immunity against shingles. Participants receive two shots two months apart and are followed for a year. The goal is to understand if the vaccine works safely in those with di…
Phase 1/2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Vaccine
Last updated Oct 10, 2026 00:00 UTC
-
New EBV vaccines enter human safety trials
Vaccine Recruiting nowThis study tests two experimental vaccines against Epstein-Barr virus (EBV), which causes mono and is linked to cancers. Researchers will give 750 healthy adults aged 18-29 three shots over several months to check for side effects and immune response. The goal is to find a safe v…
Phase 1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Vaccine
Last updated Oct 08, 2026 00:00 UTC
-
Can a shingles shot protect transplant patients? timing may be key.
Vaccine Recruiting nowThis study looks at how well the shingles vaccine Shingrix works in people who have had a stem cell transplant. About 55 adults who received the vaccine at least a year after their transplant will have their immune responses measured. Researchers want to see if the timing of the …
Phase 2 • Sponsor: University of Colorado, Denver • Aim: Vaccine
Last updated Oct 08, 2026 00:00 UTC
-
Can a new RSV vaccine shield older adults from severe lung infections?
Vaccine Recruiting nowResearchers are testing a recombinant RSV vaccine made in CHO cells to see if it prevents lower respiratory tract disease in adults aged 60 and older. The trial plans to enroll 25,000 participants, including about 30% aged 70 and above, who receive either the vaccine or a placebo…
Phase 3 • Sponsor: Beijing BeneWill Technology Development Co., Ltd • Aim: Vaccine
Last updated Oct 08, 2026 00:00 UTC
-
Could one shot stop RSV and hMPV? GSK begins human trials
Vaccine Recruiting nowThis study tests an experimental vaccine from GSK that targets two respiratory viruses: RSV and hMPV. About 1,800 adults aged 18-80 will receive different doses to check safety and immune response. The goal is to see if a single shot can protect against both viruses, which can ca…
Phase 1/2 • Sponsor: GlaxoSmithKline • Aim: Vaccine
Last updated Oct 03, 2026 00:00 UTC
-
Next-Generation polio vaccine enters human testing
Vaccine Recruiting nowThis trial tests a new recombinant polio vaccine (rPV) against the current standard IPOL vaccine in healthy adults aged 18 to 60. The goal is to see if the new vaccine is safe and triggers a strong immune response. It is a small, early-stage study to gather initial data.
Phase 1 • Sponsor: Serum Institute of India Pvt. Ltd. • Aim: Vaccine
Last updated Oct 01, 2026 00:00 UTC
-
Can updated COVID-19 shots better protect High-Risk groups?
Vaccine Recruiting nowThis Phase 3 trial tests updated versions of the BNT162b2 COVID-19 vaccine in adults and children aged 5 and older. Participants include those aged 5 to 64 with medical conditions that raise their risk of severe COVID-19, as well as everyone aged 65 and older. The study compares …
Phase 3 • Sponsor: BioNTech SE • Aim: Vaccine
Last updated Sep 30, 2026 00:00 UTC
-
New RSV vaccine aims to shield adults from severe respiratory infection
Vaccine Recruiting nowThis study tests an experimental vaccine called RSVpreF in adults to see if it is safe and triggers a strong immune response against respiratory syncytial virus (RSV). Around 540 adults in India will receive either the vaccine or a placebo. Researchers will monitor for side effec…
Phase 3 • Sponsor: Pfizer • Aim: Vaccine
Last updated Sep 26, 2026 00:00 UTC
-
Could a Double-Dose flu vaccine better protect transplant kids?
Vaccine Recruiting nowThis study compares a high-dose flu vaccine to the standard dose in 312 children aged 3-17 who have received a kidney, heart, or liver transplant within the past two years. The goal is to see if the high-dose vaccine triggers a stronger immune response and is just as safe. Partic…
Phase 2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Vaccine
Last updated Sep 26, 2026 00:00 UTC
-
New marburg vaccine trial launches: could it stop the deadly virus?
Vaccine Recruiting nowThis early-stage trial tests a new vaccine (rVSVΔG-MARV-GP) to see if it is safe and triggers an immune response against Marburg virus, a rare but severe disease. About 112 healthy adults aged 18-50 will receive either the vaccine or a placebo. The study focuses on side effects a…
Phase 1 • Sponsor: International AIDS Vaccine Initiative • Aim: Vaccine
Last updated Sep 25, 2026 00:00 UTC
-
New sudan virus vaccine enters first human tests
Vaccine Recruiting nowThis early-stage study tests a new vaccine designed to prevent Sudan virus disease, a severe illness similar to Ebola. About 112 healthy adults aged 18-50 will receive either the vaccine or a placebo to check for side effects and measure immune responses. The goal is to see if th…
Phase 1 • Sponsor: International AIDS Vaccine Initiative • Aim: Vaccine
Last updated Sep 23, 2026 00:00 UTC
-
Can mRNA technology outsmart the flu in older adults?
Vaccine Recruiting nowThis large phase 3 trial compares an investigational mRNA flu vaccine with a licensed flu vaccine in adults aged 65 and older. Each participant receives a single injection and is followed through the flu season. Researchers measure how well the mRNA vaccine prevents laboratory-co…
Phase 3 • Sponsor: GlaxoSmithKline • Aim: Vaccine
Last updated Sep 20, 2026 00:00 UTC
-
New HIV vaccine booster trial launches: could it strengthen immunity?
Vaccine Recruiting nowThis early-stage trial is testing a new HIV vaccine booster called VRIPRO, given with an immune-boosting adjuvant, in 40 healthy adults aged 18-60 who previously received an HIV vaccine in the HVTN 706 study. Participants will get three shots over 24 weeks. The main goals are to …
Phase 1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Vaccine
Last updated Sep 20, 2026 00:00 UTC
-
Could a vaccine stop the virus behind mono, cancer, and MS?
Vaccine Recruiting nowThis early-stage study is testing two new vaccines (V350A and V350B) designed to prevent diseases caused by the Epstein-Barr virus (EBV), which can cause infectious mononucleosis and is linked to certain cancers and multiple sclerosis. The study will enroll 250 healthy adults and…
Phase 1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Vaccine
Last updated Sep 19, 2026 00:00 UTC
-
Could a vaccine before liver transplant cut antiviral use?
Vaccine Recruiting nowThis phase 2 trial tests a CMV vaccine (CMV-MVA Triplex) given before a liver transplant to see if it reduces the need for antiviral drugs after surgery. The study enrolls 416 CMV-negative adults awaiting a liver transplant from a CMV-positive donor. Participants receive two vacc…
Phase 2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Vaccine
Last updated Sep 18, 2026 00:00 UTC
-
Can a TB vaccine be upgraded to fight RSV in seniors?
Vaccine Recruiting nowThis trial is testing a new vaccine called rBCG-N-RSV, which is based on the BCG vaccine (used for tuberculosis) but modified to also target respiratory syncytial virus (RSV). The study involves 200 adults over 60 years old, who will receive either this new vaccine or the standar…
Phase 2 • Sponsor: Biothervax SpA • Aim: Vaccine
Last updated Sep 17, 2026 00:00 UTC
-
Experimental flu vaccine enters human testing
Vaccine Recruiting nowThis early-stage trial tests an experimental flu vaccine called FluMos-v2, with or without an adjuvant (ALFQ), in 45 healthy adults aged 18-50. Participants receive two shots four months apart and are followed for 15 months. The goal is to check safety and how well the vaccine tr…
Phase 1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Vaccine
Last updated Sep 17, 2026 00:00 UTC
-
Could a new vaccine beat chickenpox? large trial underway
Vaccine Recruiting nowThis study tests a new chickenpox vaccine called NBP608 in about 780 children aged 1 to 12 years. The vaccine is compared to licensed vaccines to see how well it triggers immunity and if it is safe. Children receive one or two shots, and researchers monitor their immune response …
Phase 3 • Sponsor: SK Bioscience Co., Ltd. • Aim: Vaccine
Last updated Sep 17, 2026 00:00 UTC
-
Can a new vaccine shield us from bird flu?
Vaccine Recruiting nowThis trial is testing an experimental vaccine against H5N8, a type of bird flu, in healthy adults aged 18 and older. The vaccine is made using eggs and is given as two shots, with or without an adjuvant—a substance that may boost the immune response. The study aims to see if the …
Phase 1/2 • Sponsor: Sanofi • Aim: Vaccine
Last updated Sep 17, 2026 00:00 UTC
-
MRNA shot takes aim at the nerve pain of shingles
Vaccine Recruiting nowResearchers are testing an experimental mRNA vaccine called ABO1108 to see whether it can prevent herpes zoster, the painful rash also known as shingles. The trial enrolls adults aged 40 and older, including people whose long-term conditions are stable. Participants receive two i…
Phase 3 • Sponsor: Suzhou Abogen Biosciences Co., Ltd. • Aim: Vaccine
Last updated Sep 16, 2026 00:00 UTC
-
New mRNA HIV vaccines enter early human testing
Vaccine Recruiting nowThis early-stage trial will test two experimental mRNA vaccines designed to teach the immune system to make antibodies that target HIV. About 42 adults with well-controlled HIV will receive the vaccines and then temporarily pause their regular HIV medication under close monitorin…
Phase 1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Vaccine
Last updated Sep 16, 2026 00:00 UTC
-
Norovirus vaccine candidate put to the test in first human trial
Vaccine Recruiting nowResearchers are testing an experimental vaccine called INT101 to see if it is safe and can trigger an immune response against norovirus. The trial enrolls about 30 healthy adults aged 19 to 48. Participants receive either a low dose, a high dose, or a placebo as three intramuscul…
Phase 1 • Sponsor: InThera Inc. Korea • Aim: Vaccine
Last updated Sep 16, 2026 00:00 UTC
-
New mRNA vaccine aims to shield against RSV
Vaccine Recruiting nowThis early-stage trial tests an experimental mRNA vaccine called YKYY025 designed to protect against respiratory syncytial virus (RSV). Healthy adults aged 18 and older receive a single injection of either the vaccine or a placebo. Researchers monitor safety, side effects, and im…
Phase 1 • Sponsor: Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd. • Aim: Vaccine
Last updated Sep 12, 2026 00:00 UTC
-
New flu vaccine trial aims for stronger, Longer-Lasting protection
Vaccine Recruiting nowThis early-stage study tests a new flu vaccine (STEMos1) in 56 healthy adults aged 18-50. Half of the participants get the vaccine with an adjuvant (a substance that boosts the immune response), and half get it without. The goal is to check safety and how well the vaccine trigger…
Phase 1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Vaccine
Last updated Sep 11, 2026 00:00 UTC
-
Can a Birth-Dose polio vaccine block the virus in Babies' guts?
Vaccine Recruiting nowResearchers are testing whether a new oral polio vaccine called nOPV2, given at birth, helps infants block type 2 poliovirus in their intestines. The trial enrolls 740 healthy newborns who have received standard injected polio vaccines. Scientists will check stool samples for sig…
Phase 3 • Sponsor: Fidec Corporation • Aim: Vaccine
Last updated Sep 11, 2026 00:00 UTC
-
Blood cancer patients needed for flu vaccine showdown
Vaccine Recruiting nowThis study compares three different flu vaccines in 60 adults with blood cancers like leukemia or lymphoma. The goal is to see which vaccine triggers the strongest immune response in people with weakened immune systems. Participants will receive one of the vaccines and have their…
Phase 3 • Sponsor: Asan Medical Center • Aim: Vaccine
Last updated Sep 03, 2026 00:00 UTC
-
Massive mpox vaccine trial launches in DRC: could it stop the outbreak?
Vaccine Recruiting nowThis large study will test the LC16m8 mpox vaccine in nearly 12,000 people aged one year and older in the Democratic Republic of Congo. Researchers want to see if the vaccine can prevent mpox disease and monitor its safety. Participants will receive the vaccine as part of the gov…
Sponsor: International Vaccine Institute • Aim: Vaccine
Last updated Sep 02, 2026 00:00 UTC
-
Could a single HPV shot match the standard regimen?
Vaccine Recruiting nowThis trial tests whether a single dose of the 9-valent HPV vaccine triggers the same immune response as two doses in healthy adults aged 18 to 45. Researchers will measure antibody and B cell responses in blood, lymph nodes, and bone marrow. The goal is to understand how the vacc…
Phase 4 • Sponsor: Emory University • Aim: Vaccine
Last updated Sep 02, 2026 00:00 UTC
-
Can a personalized video and phone call get more teens the HPV vaccine?
Vaccine Recruiting nowThis study tests whether a combination of a culturally tailored video message from an HPV cancer survivor and a reminder phone call can increase the number of adolescents aged 10-12 who get the HPV vaccine. The intervention is delivered through a patient portal and direct outreac…
Sponsor: University of California, Davis • Aim: Vaccine
Last updated Aug 13, 2026 00:00 UTC
-
Can the HPV vaccine fully protect transgender women and people with HIV?
Vaccine Recruiting nowThis study is testing how well the 9-valent HPV vaccine (Gardasil9) triggers an immune response in people born male who have used estrogen or androgen blockers, including those living with HIV. Participants receive three doses of the vaccine over six months, and their immune resp…
Phase 2 • Sponsor: University of Maryland, Baltimore • Aim: Vaccine
Last updated Aug 07, 2026 00:00 UTC
-
Could longer or stronger antivirals beat COVID in vulnerable patients?
Disease control Recruiting nowThis study looks at whether giving a longer course (10 days instead of 5) or adding another antiviral (remdesivir) to the standard Paxlovid treatment helps immunocompromised people clear COVID-19 faster. About 256 adults with mild or no symptoms will be randomly assigned to diffe…
Phase 2 • Sponsor: ANRS, Emerging Infectious Diseases • Aim: Disease control
Last updated Oct 20, 2026 06:00 UTC
-
Can Long-Acting injections keep HIV in check?
Disease control Recruiting nowResearchers are following 1,500 people with HIV who start long-acting injections of cabotegravir and rilpivirine. The study collects clinical and lab data over time to see how well the regimen controls the virus and what factors affect tolerability, side effects, and quality of l…
Sponsor: Castagna Antonella • Aim: Disease control
Last updated Oct 20, 2026 06:00 UTC
-
New vaccine could help throat cancer patients avoid radiation
Disease control Recruiting nowThis phase 2 trial tests whether adding an experimental vaccine (PRGN-2009) to standard chemotherapy can improve outcomes for people with newly diagnosed HPV-related throat cancer, potentially allowing them to skip radiation. About 70 adults will receive either chemo alone or che…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Oct 20, 2026 06:00 UTC
-
Clinic culture change aims to boost HIV outcomes for black patients
Disease control Recruiting nowThis study tests a program called ARC that helps HIV clinics improve their work environment and reduce discrimination. Researchers will compare viral suppression and care retention in clinics using ARC versus standard care. The goal is to see if better clinic culture leads to bet…
Sponsor: University of Pennsylvania • Aim: Disease control
Last updated Oct 20, 2026 06:00 UTC
-
Kids with HIV get continued access to lifesaving meds in new study
Disease control Recruiting nowThis study offers continued access to HIV medications for children and adolescents who completed a previous Gilead HIV treatment study. About 350 participants will receive their study drug or switch to a standard HIV medication, and researchers will monitor for side effects. The …
Phase 4 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Oct 20, 2026 06:00 UTC
-
New study aims to help people with HIV quit smoking in south africa
Disease control Recruiting nowThis study tests two smoking cessation methods—varenicline pills and nicotine patches with gum—in 660 people with HIV in South Africa. Participants will receive one of these treatments for 12 weeks, along with counseling. The goal is to see which approach works best to help them …
Phase 2/3 • Sponsor: Johns Hopkins University • Aim: Disease control
Last updated Oct 20, 2026 06:00 UTC
-
New drug could beat virus threat in transplant patients
Disease control Recruiting nowThis study tests a new drug, brincidofovir, against the current treatment cidofovir for adenovirus infection in children and adults who have had a stem cell transplant. About 180 participants will receive one of the two drugs intravenously until the virus is cleared or up to 12 w…
Phase 3 • Sponsor: SymBio Pharmaceuticals • Aim: Disease control
Last updated Oct 20, 2026 06:00 UTC
-
Donor immune cells take on Virus-Linked cancer after transplant
Disease control Recruiting nowThis phase 3 trial tests tabelecleucel, a cell therapy made from donor immune cells, in 115 organ or stem cell transplant patients who developed a rare cancer (EBV+ PTLD) after standard treatment failed. The goal is to see if it can shrink tumors and improve outcomes. Participant…
Phase 3 • Sponsor: Pierre Fabre Medicament • Aim: Disease control
Last updated Oct 20, 2026 06:00 UTC
-
New blood product tested for safer liver transplants
Disease control Recruiting nowThis study tests two blood products used to control bleeding during liver transplant surgery. It compares a newer product, Intercept Fibrinogen Complex, to standard cryoprecipitate. The goal is to see if the newer product works as well or better at stopping bleeding. The study wi…
Phase 4 • Sponsor: Trauma Hemostatis and Oxygenation Research (THOR) Network • Aim: Disease control
Last updated Oct 20, 2026 06:00 UTC
-
New drug cocktail targets Virus-Linked cancers in early trial
Disease control Recruiting nowThis phase 1 study tests a combination of two drugs, pomalidomide (a pill) and nivolumab (an infusion), in adults with cancers caused by viruses like Epstein-Barr, HPV, or hepatitis. The goal is to find a safe dose and see if the drugs can shrink tumors. Up to 58 people with Kapo…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Oct 18, 2026 00:00 UTC
-
New hope for brain infection: experimental combo tackles tuberculous meningitis
Disease control Recruiting nowThis study tests a new combination of medicines (BPaLMZ) against the standard treatment for tuberculous meningitis, a serious brain infection. About 240 adults, including those living with HIV, will take part. The goal is to see if the new combo helps more people survive and reco…
Phase 2 • Sponsor: David Boulware • Aim: Disease control
Last updated Oct 18, 2026 00:00 UTC
-
New hope for HIV patients with blood cancer: safer bone marrow transplants on the horizon?
Disease control Recruiting nowThis study tests whether a combination of three drugs (cyclophosphamide, bortezomib, and maraviroc) can safely prevent graft-versus-host disease after a half-matched bone marrow transplant in people living with HIV who also have a blood cancer. The trial involves 265 participants…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Oct 18, 2026 00:00 UTC
-
Promising new combo tackles tough leukemia
Disease control Recruiting nowThis phase 2 trial is testing a five-drug combination for a rare, aggressive type of T-cell leukemia called ETP-ALL. The study aims to see if this mix can help more patients achieve remission after their first treatment. About 27 newly diagnosed adults will receive the drugs, and…
Phase 2 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Oct 18, 2026 00:00 UTC
-
Light therapy shows promise against HPV-Linked cervical precancer
Disease control Recruiting nowThis study tests a treatment called photodynamic therapy (PDT) for women with low-grade cervical precancer caused by HPV types 16 or 18. A photosensitizing cream is applied to the cervix, then activated with light to destroy abnormal cells. The trial will compare 225 women who re…
Sponsor: Second Affiliated Hospital, Zhejiang University, School of Medicine • Aim: Disease control
Last updated Oct 18, 2026 00:00 UTC
-
Cancer drug nivolumab takes on EBV-Linked tumors in new trial
Disease control Recruiting nowThis phase 2 trial tests whether the drug nivolumab can slow or stop the growth of Epstein-Barr virus (EBV)-positive lymphoproliferative disorders and non-Hodgkin lymphomas. About 40 people aged 12 and older whose cancers have not responded to standard therapy will receive nivolu…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Oct 18, 2026 00:00 UTC
-
New study targets rare Virus-Driven inflammatory syndrome
Disease control Recruiting nowThis study looks at a newly recognized disease called KSHV Inflammatory Cytokine Syndrome (KICS), caused by a virus that can also lead to certain cancers. Researchers aim to learn more about the disease and test experimental treatments, including antiviral and chemotherapy drugs,…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Oct 18, 2026 00:00 UTC
-
New hope for rare cancers: daratumumab trial targets Hard-to-Treat lymphomas
Disease control Recruiting nowThis phase 2 trial tests the drug daratumumab in 28 adults with three rare and aggressive blood cancers: primary effusion lymphoma, plasmablastic lymphoma, and multicentric Castleman disease. Participants must have failed standard therapy or be unable to receive it. Daratumumab i…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Oct 18, 2026 00:00 UTC
-
New drug aims to stop kidney transplant rejection without antibodies
Disease control Recruiting nowThis study tests a drug called felzartamab in people who received a kidney transplant and later developed microvascular inflammation (MVI), a type of injury to small blood vessels in the new kidney that can lead to serious problems. The trial includes 81 participants who will rec…
Phase 2 • Sponsor: Biogen • Aim: Disease control
Last updated Oct 18, 2026 00:00 UTC
-
Could a breast cancer drug tame kaposi sarcoma?
Disease control Recruiting nowThis study tests a drug called abemaciclib, already used for breast cancer, in people with Kaposi sarcoma (KS), both with and without HIV. The goal is to find a safe dose and see if it can shrink KS tumors. About 111 adults will take the drug daily in 28-day cycles until their ca…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Oct 18, 2026 00:00 UTC
-
New drug combo aims to outsmart kaposi sarcoma tumors
Disease control Recruiting nowThis study tests two drugs, PDS01ADC and M7824, that work with the immune system to fight Kaposi sarcoma (KS), a cancer often linked to HIV or organ transplants. The trial enrolls 80 adults with advanced KS that has not responded well to prior therapy. Participants receive PDS01A…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Oct 18, 2026 00:00 UTC
-
Can an extra drug flush out hidden HIV? new study seeks answers
Disease control Recruiting nowThis study tests whether adding the drug lenacapavir to standard HIV treatment can reduce the hidden HIV reservoirs that remain in the body. About 50 adults with well-controlled HIV will either continue their usual therapy or receive lenacapavir injections plus pills. Researchers…
Phase 1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Oct 17, 2026 00:00 UTC
-
Experimental combo targets rare leukemia
Disease control Recruiting nowThis early-stage trial tests adding lenalidomide to standard chemotherapy (EPOCH) for adult T-cell leukemia-lymphoma, a rare and aggressive blood cancer linked to HTLV-1 infection. The main goal is to find the safest dose of lenalidomide when used with chemo. Up to 30 adults with…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Oct 17, 2026 00:00 UTC
-
New pill aims to keep High-Risk COVID patients out of the hospital
Disease control Recruiting nowThis study tests an oral medication called ibuzatrelvir in adults and teens with COVID-19 who are not hospitalized but have a high risk of becoming severely ill. Participants will receive either the drug or a placebo for 5 days, and researchers will track whether it reduces emerg…
Phase 3 • Sponsor: Pfizer • Aim: Disease control
Last updated Oct 17, 2026 00:00 UTC
-
Could a shot replace daily HIV pills? new trial tests Two-Injection combo
Disease control Recruiting nowThis Phase 2 trial tests whether switching to a combination of two injectable drugs, GS-3242 and lenacapavir, works as well as staying on the daily pill Biktarvy for people with HIV who already have the virus under control. About 175 participants will be randomly assigned to eith…
Phase 2 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Oct 17, 2026 00:00 UTC
-
New program aims to boost HIV medication adherence in black women
Disease control Recruiting nowThis study tests a 10-session counseling program called STEP-AD for Black women living with HIV who have a history of trauma. The goal is to help them stick to their HIV medication and achieve viral suppression. Researchers will enroll 250 participants and compare the program to …
Sponsor: University of Miami • Aim: Disease control
Last updated Oct 17, 2026 00:00 UTC
-
New strategy aims to boost addiction treatment and curb HIV in central asia
Disease control Recruiting nowThis study tests a program to expand medication-assisted treatment for opioid addiction in Kazakhstan, Kyrgyzstan, and Tajikistan. Researchers will train local health officials and track how many people start and stay on treatment. The goal is to reduce HIV spread among people wh…
Sponsor: Yale University • Aim: Disease control
Last updated Oct 16, 2026 00:00 UTC
-
Can a second RSV shot in pregnancy protect more babies?
Disease control Recruiting nowThis study tests whether giving a second dose of an RSV vaccine to pregnant women who already received it in a prior pregnancy is safe and boosts immunity. About 550 women aged 18-49, between 24-36 weeks pregnant, will receive either the vaccine or a placebo. Researchers will tra…
Phase 3 • Sponsor: Pfizer • Aim: Disease control
Last updated Oct 16, 2026 00:00 UTC
-
New pill combo aims to protect vulnerable from severe COVID
Disease control Recruiting nowThis phase 3 trial tests a new antiviral pill, ibuzatrelvir, alone or with an IV drug (remdesivir) in 300 adults with weak immune systems who have mild-to-moderate COVID-19. The goal is to see if the combination prevents hospitalizations or worsening symptoms better than remdesiv…
Phase 3 • Sponsor: Pfizer • Aim: Disease control
Last updated Oct 16, 2026 00:00 UTC
-
Can two antibodies help people with HIV ditch daily pills?
Disease control Recruiting nowThis study tests whether giving two powerful HIV-fighting antibodies along with standard HIV medication (ART) to people diagnosed very early with HIV can help them control the virus without daily pills later. 48 adults with acute HIV infection will receive either the antibodies o…
Phase 2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Oct 16, 2026 00:00 UTC
-
Light therapy could replace surgery for cervical precancer
Disease control Recruiting nowThis study compares a light-activated gel treatment (ALA-PDT) to standard surgery (LEEP) for women with high-grade cervical precancer (HSIL/CIN2). About 560 women will receive either the gel plus red light therapy or surgery. The goal is to see if the gel treatment works as well …
Sponsor: Second Affiliated Hospital, Zhejiang University, School of Medicine • Aim: Disease control
Last updated Oct 16, 2026 00:00 UTC
-
Daily pill offers new route for Hard-to-Treat T-Cell lymphomas
Disease control Expanded accessThis medical access program provides valemetostat tosylate, an oral drug already approved in Japan, to adults with peripheral T-cell lymphoma that has come back or stopped responding to at least two prior treatments. Participants take a 200 mg pill once daily in 28-day cycles for…
Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
New antiviral pill aims to keep High-Risk COVID patients out of hospital
Disease control Recruiting nowThis study tests whether the antiviral drug molnupiravir can prevent severe illness from COVID-19 in adults at high risk. About 3,000 non-hospitalized participants will take either molnupiravir or a placebo for 5 days. The main goal is to see if the drug reduces hospitalizations,…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
Could a weekly pill replace daily HIV treatment? new study aims to find out.
Disease control Recruiting nowThis study tests whether a once-weekly combination of two experimental drugs (islatravir and ulonivirine) works as well as the standard daily three-drug pill Biktarvy for people newly diagnosed with HIV-1. About 570 adults who have never taken HIV medication will be randomly assi…
Phase 2/3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
New shot aims to cure hepatitis b – early trial underway
Disease control Recruiting nowThis Phase 2 trial tests an experimental drug called AHB-137 in 84 adults with chronic hepatitis B who are already on antiviral therapy. The goal is to see if AHB-137 can clear the hepatitis B surface antigen and keep the virus under control, potentially leading to a functional c…
Phase 2 • Sponsor: AusperBio Therapeutics Inc. • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
Could a shot replace daily HIV pills? new trial tests injectable combo
Disease control Recruiting nowThis study tests whether an injectable combination of two experimental drugs, GS-3242 and lenacapavir, can control HIV-1 as well as the daily pill Biktarvy. About 700 people with HIV who have never taken antiviral treatment will receive either the injectable regimen or the standa…
Phase 2/3 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
New hope for young transplant patients: drug trial targets dangerous virus
Disease control Recruiting nowThis study is testing the drug letermovir to prevent cytomegalovirus (CMV) infection in children and teens who have had a kidney transplant and weigh less than 40 kg. About 40 participants will receive the drug to see how it moves through their bodies and if it is safe. The goal …
Phase 1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
Old drug, new hope? emetine trial targets dengue deaths
Disease control Recruiting nowThis study tests whether the drug emetine can help people hospitalized with dengue fever. About 600 adults aged 18 to 65 will take either a low or high dose of emetine or a placebo pill for 7 days. Researchers will track if the drug reduces deaths or stops the disease from becomi…
Phase 2/3 • Sponsor: Johns Hopkins University • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
Experimental combo targets tough T-Cell lymphoma
Disease control Recruiting nowThis phase 1 trial is testing whether combining two drugs, azacitidine and abatacept, can shrink tumors in adults with T-cell lymphoma that has relapsed or not responded to prior treatment. Up to 20 participants will receive the drugs in 28-day cycles for up to 13 cycles. The stu…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Oct 11, 2026 00:00 UTC
-
Can a new pill keep High-Risk COVID-19 patients out of the hospital?
Disease control Recruiting nowThis phase 3 trial is testing whether the oral antiviral secutrelvir can prevent severe COVID-19 in people who are at high risk for complications. Participants with mild symptoms and confirmed SARS-CoV-2 infection will receive either secutrelvir or a placebo. The study will measu…
Phase 3 • Sponsor: Shionogi • Aim: Disease control
Last updated Oct 11, 2026 00:00 UTC
-
Can a 5-Minute test and Same-Day pills cure more hepatitis c?
Disease control Recruiting nowResearchers in Armenia, Georgia, and Tanzania are comparing two ways to deliver hepatitis C care to people who inject drugs. One model confirms infection with an RNA test before starting sofosbuvir/velpatasvir, a daily pill that cures most hepatitis C. The other starts the same p…
Early phase 1 • Sponsor: Médecins du Monde • Aim: Disease control
Last updated Oct 11, 2026 00:00 UTC
-
Ebola antibody cocktail made available in emergency outbreak
Disease control Expanded accessThis program provides emergency access to REGN-EB3, a combination of three antibodies, for people with confirmed Ebola virus disease. It is available to both adults and children in Ebola-affected regions, including pregnant women. The goal is to offer a potential treatment option…
Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Oct 11, 2026 00:00 UTC
-
New study aims to help pregnant moms with HIV thrive
Disease control Recruiting nowThis study tests a program called Tunawiri (meaning 'thrive') that adds mental health screening, counseling, and support to regular HIV care for pregnant and postpartum women in Kenya. The goal is to improve depression, anxiety, and HIV treatment success. Nine hundred women will …
Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Oct 10, 2026 00:00 UTC
-
Fighting stigma to fight HIV: a new program aims to keep women in care
Disease control Recruiting nowThis study tests a program called Light Inside, designed to reduce stigma for women living with HIV who use drugs. The program involves five small-group sessions that teach coping skills and communication strategies to help participants stay engaged in HIV care and adhere to thei…
Sponsor: Johns Hopkins Bloomberg School of Public Health • Aim: Disease control
Last updated Oct 10, 2026 00:00 UTC
-
New hope for hepatitis delta: phase 3 trial launches
Disease control Recruiting nowThis phase 3 trial compares a new drug, brelovitug, to an existing treatment (bulevirtide) for chronic hepatitis delta, a serious liver infection. About 172 adults with the infection will receive either drug to see which better controls the virus and normalizes liver enzymes. The…
Phase 3 • Sponsor: Mirum Pharmaceuticals, Inc. • Aim: Disease control
Last updated Oct 10, 2026 00:00 UTC
-
Can a simple infusion shield kidney transplants from a dangerous virus?
Disease control Recruiting nowThis study is testing whether a drug called Cytogam (CMVIG) can prevent cytomegalovirus (CMV) infection in kidney transplant patients who are switching to a new immunosuppressant. The researchers will measure antibody levels in 30 adult patients over 8 weeks to see how the drug w…
Phase 1/2 • Sponsor: University of Minnesota • Aim: Disease control
Last updated Oct 09, 2026 00:00 UTC
-
New vaccine aims to shield kids from Post-Transplant virus
Disease control Recruiting nowThis study tests a vaccine called CMV-MVA Triplex in 80 children who have had a stem cell transplant and are at risk for CMV infection. The goal is to find the best dose and see if it safely prevents CMV reactivation. Participants receive the vaccine and are monitored for side ef…
Phase 1/2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Oct 09, 2026 00:00 UTC
-
Can peer support and case management improve life for older rural HIV patients?
Disease control Recruiting nowThis study tests two remote programs—peer support groups and strengths-based case management—for adults aged 50+ living with HIV in rural Southern U.S. counties. The goal is to see if these programs help with viral suppression, medication adherence, quality of life, and depressio…
Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Oct 08, 2026 00:00 UTC
-
New hope: drug may shield kids from virus after transplant
Disease control Recruiting nowThis study tests whether the antiviral drug letermovir can prevent cytomegalovirus (CMV) infection in children and teens who have had a stem cell transplant. About 105 participants aged 2 to 17 will receive letermovir and be monitored for 14 weeks. The goal is to see if the drug …
Phase 3 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Oct 08, 2026 00:00 UTC
-
Experimental drug aims to reverse liver damage in rare triple condition
Disease control Recruiting nowThis study tests a drug called foscenvivint in people with liver cirrhosis caused by HIV and hepatitis C co-infection who also have hemophilia. Participants receive the drug once a week for 24 weeks. Researchers will check if the drug improves liver function and is safe to use.
Phase 2 • Sponsor: Kiminori Kimura, MD • Aim: Disease control
Last updated Oct 07, 2026 00:00 UTC
-
Experimental virus and CAR t combo takes on Hard-to-Treat GI cancers
Disease control Recruiting nowThis early-stage trial is testing a new treatment called DISP-10 for people with advanced gastrointestinal cancers, including colorectal and stomach cancers. The treatment combines a virus (DV-10) with specially engineered immune cells (CAR T cells) to attack cancer. The study ai…
Phase 1 • Sponsor: Dispatch Biotherapeutics • Aim: Disease control
Last updated Oct 07, 2026 00:00 UTC
-
Could an MS drug tame a rare Virus-Caused paralysis?
Disease control Recruiting nowThis study tests whether teriflunomide, a drug already used for multiple sclerosis, can help people with a rare spinal cord disease called HAM/TSP caused by the HTLV-1 virus. About 24 adults will take the drug daily for 9 months to see if it reduces harmful immune activity and im…
Phase 1/2 • Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) • Aim: Disease control
Last updated Oct 07, 2026 00:00 UTC
-
Could a common heart drug treat kaposi sarcoma?
Disease control Recruiting nowThis phase 2 trial tests whether propranolol, a drug usually used for high blood pressure, can treat Kaposi sarcoma. About 25 children and adults will take propranolol pills for up to 24 weeks. Researchers will measure how many participants see their tumors shrink or disappear, a…
Phase 2 • Sponsor: AIDS Malignancy Consortium • Aim: Disease control
Last updated Oct 07, 2026 00:00 UTC
-
Could a bone drug help control HIV?
Disease control Recruiting nowThis small Phase 2 trial tests whether alendronate, a drug used for bone health, can reduce the hidden HIV reservoir in people already on antiretroviral therapy. About 30 participants will receive either alendronate or a placebo, and researchers will measure changes in HIV DNA an…
Phase 2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Oct 07, 2026 00:00 UTC
-
New drug aims to save lives in severe viral lung infections
Disease control Recruiting nowThis large Phase 3 trial is testing an experimental drug called tozorakimab in about 2,870 adults hospitalized with a viral lung infection who need extra oxygen. Participants receive either a single dose of tozorakimab or a placebo, added to standard care. The main goal is to see…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Oct 04, 2026 00:00 UTC
-
New study combines trauma therapy with HIV prevention for transgender community
Disease control Recruiting nowThis pilot study will test a program that combines a trauma-focused therapy (STAIR) with peer-led HIV prevention (PrEP) support for transgender and nonbinary people who have experienced violence. The goal is to see if this combined approach is acceptable, feasible, and helps impr…
Sponsor: San Diego State University • Aim: Disease control
Last updated Oct 04, 2026 00:00 UTC
-
Could a buddy system for HIV care improve lives?
Disease control Recruiting nowThis study tests whether giving people with HIV or those taking PrEP two dedicated case managers helps them achieve better financial stability, food security, and health outcomes. Participants will work with their case managers to set goals and stay connected to care. The trial c…
Sponsor: University of Chicago • Aim: Disease control
Last updated Oct 04, 2026 00:00 UTC
-
Heart transplant patients may get safer virus protection
Disease control Recruiting nowThis study tests whether a newer drug, letermovir, is safer and more effective than the standard valganciclovir for preventing CMV infection in heart transplant recipients. About 150 moderate- to high-risk adults will be enrolled. The main focus is on reducing side effects like l…
Phase 2/3 • Sponsor: Columbia University • Aim: Disease control
Last updated Oct 04, 2026 00:00 UTC
-
Can an antiviral drug stop RSV in vulnerable patients?
Disease control Recruiting nowThis study tests whether the antiviral drug remdesivir can help treat RSV (a common respiratory virus) in people whose immune systems are weakened by certain cancer treatments or autoimmune therapies. About 60 adults with confirmed RSV will receive remdesivir intravenously. The m…
Phase 2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Oct 03, 2026 00:00 UTC
-
Could placental wraps heal stubborn ulcers? new trial begins
Disease control Recruiting nowThis study tests whether special wraps made from human placental membrane can help heal diabetic foot ulcers and venous leg ulcers that won't close on their own. About 50 adults with diabetes or venous disease will receive weekly applications of one of four placental membrane pro…
Sponsor: BioLab Holdings • Aim: Disease control
Last updated Oct 03, 2026 00:00 UTC
-
Can a phone app help people with HIV kick the smoking habit?
Disease control Recruiting nowThis study compares two smartphone apps designed to help people living with HIV quit smoking. Participants will use one of the apps for about six months and also receive nicotine patches and gum. The goal is to see which app works better at helping people stay smoke-free, using b…
Sponsor: Wake Forest University Health Sciences • Aim: Disease control
Last updated Oct 02, 2026 00:00 UTC
-
New RSV drug trial aims to protect vulnerable adults
Disease control Recruiting nowThis study tests an experimental antiviral drug called S-337395 in adults with RSV who are at high risk for severe illness. Participants must have symptoms for less than 72 hours and a confirmed RSV infection. The goal is to see if the drug can lower the amount of virus in the bo…
Phase 2 • Sponsor: Shionogi • Aim: Disease control
Last updated Oct 01, 2026 00:00 UTC
-
Choice over standard care may boost HIV treatment in Justice-Involved groups
Disease control Recruiting nowThis study compares two patient navigation models for people recently involved in the criminal legal system who have substance use disorders. One group gets standard navigation, while the other can choose from a menu of services like in-person clinics, mobile health units, or tel…
Sponsor: Yale University • Aim: Disease control
Last updated Oct 01, 2026 00:00 UTC
-
New Ultra-Long-Acting HIV shots could mean fewer doses for patients
Disease control Recruiting nowThis study tests whether a new ultra-long-acting injectable HIV medication works as well as the current long-acting version. About 564 adults and teens with well-controlled HIV will receive either the ultra-long-acting or the standard long-acting shots. The goal is to see if the …
Phase 3 • Sponsor: ViiV Healthcare • Aim: Disease control
Last updated Sep 30, 2026 00:00 UTC
-
Can existing COVID drug beat dengue? new trial begins
Disease control Recruiting nowThis phase 2 trial is testing two antivirals—molnupiravir (used for COVID-19) and a lab-made antibody called VIS513—in 500 people with early dengue. Participants must have had fever for less than 48 hours and a positive rapid test. The goal is to see if these drugs can clear the …
Phase 2 • Sponsor: Oxford University Clinical Research Unit, Vietnam • Aim: Disease control
Last updated Sep 30, 2026 00:00 UTC
-
New drug IB-001 enters first human tests for chronic hepatitis b
Disease control Recruiting nowThis early-stage study tests a new drug called IB-001 for chronic hepatitis B. It will first check safety in up to 60 healthy volunteers, then test multiple doses in about 30 people with chronic hepatitis B. The main goal is to see if the drug is safe and how the body handles it.
Phase 1 • Sponsor: IntegerBio • Aim: Disease control
Last updated Sep 30, 2026 00:00 UTC
-
New hepatitis b drug enters first human tests
Disease control Recruiting nowThis early-stage trial is testing an experimental drug called GIGA-2339 in 48 adults with chronic hepatitis B. The main goal is to check if the drug is safe and how the body processes it. Participants will receive either GIGA-2339 or a placebo by IV infusion, and researchers will…
Phase 1 • Sponsor: GigaGen, Inc. • Aim: Disease control
Last updated Sep 27, 2026 00:00 UTC
-
Can a simple supplement help COVID-19 patients with liver disease?
Disease control Recruiting nowThis study tests whether an HMB-enriched amino acid supplement can reverse muscle loss and improve recovery in 48 patients with alcoholic liver disease and COVID-19 pneumonia. Participants receive either the HMB supplement or a balanced amino acid mix for 90 days. Researchers wil…
Sponsor: The Cleveland Clinic • Aim: Disease control
Last updated Sep 27, 2026 00:00 UTC
-
Could a rheumatoid arthritis drug ease long COVID brain fog?
Disease control Recruiting nowThis study tests whether baricitinib, a drug used for arthritis, can improve thinking, physical function, and quality of life in people with Long COVID. About 550 adults who had COVID-19 at least 6 months ago will receive either baricitinib or a placebo for 6 months. The main goa…
Phase 3 • Sponsor: Wes Ely • Aim: Disease control
Last updated Sep 27, 2026 00:00 UTC
-
Can a pharmacist help people with HIV avoid falls and brain fog? new study aims to find out.
Disease control Recruiting nowThis pilot study tests a program where a clinical pharmacist talks with people with HIV about the risks of drinking alcohol (with or without cannabis) while taking multiple medications, especially those that affect the brain. The goal is to see if this approach can reduce falls a…
Phase 1 • Sponsor: Yale University • Aim: Disease control
Last updated Sep 27, 2026 00:00 UTC
-
New shot aims to tame hepatitis b without daily pills
Disease control Recruiting nowThis phase 2 trial tests an experimental drug called AHB-137 in 70 adults with chronic hepatitis B who are already on antiviral pills. The drug is given as a shot under the skin. The goal is to see if it can lower the virus to undetectable levels and allow some people to stop the…
Phase 2 • Sponsor: AusperBio Therapeutics Inc. • Aim: Disease control
Last updated Sep 26, 2026 00:00 UTC
-
Immune cells from donors take on viruses in transplant patients
Disease control Recruiting nowThis early study tests whether immune cells from a donor can safely fight cytomegalovirus (CMV) or adenovirus (AdV) infections in people who have had a stem cell or solid organ transplant. About 20 participants will receive these virus-specific T-cells intravenously. The main goa…
Early phase 1 • Sponsor: Sumithira Vasu • Aim: Disease control
Last updated Sep 26, 2026 00:00 UTC
-
HIV drug shows promise to reboot immune system in Non-Responders
Disease control Recruiting nowThis study tests whether adding the HIV drug rilpivirine to standard treatment can help people with HIV whose immune systems haven't fully recovered. About 21 adults with low CD4 counts despite years of successful viral suppression will receive rilpivirine for 48 weeks. The goal …
Phase 2 • Sponsor: Beijing 302 Hospital • Aim: Disease control
Last updated Sep 26, 2026 00:00 UTC
-
New flu drug under watch in kids: will it work and stop family spread?
Disease control Recruiting nowThis study looks at how well the flu drug baloxavir marboxil works in children under 12 and whether it stops the flu from spreading to family members. About 1,100 kids with flu symptoms will take the drug, and researchers will check for drug resistance and track infections in hou…
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Sep 26, 2026 00:00 UTC
-
New HIV combo pill tested for rapid start in 100 patients
Disease control Recruiting nowThis study tests whether a once-daily pill containing doravirine, lamivudine, and tenofovir can quickly control HIV in people who have never taken HIV drugs before. One hundred newly diagnosed adults will take the pill for 48 weeks. The main goal is to see how many have undetecta…
Phase 4 • Sponsor: Fundación Huésped • Aim: Disease control
Last updated Sep 25, 2026 00:00 UTC
-
Can a new drug, GS-0415, help keep HIV in check? a First-in-Human trial aims to find out
Disease control Recruiting nowThis early-stage trial is testing an experimental drug called GS-0415 in people with HIV who already have the virus well-controlled by standard antiretroviral therapy. The study will give single and multiple doses of GS-0415 to evaluate its safety, tolerability, and how the body …
Phase 1 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Sep 25, 2026 00:00 UTC
-
New program aims to boost HIV viral suppression in latino community
Disease control Recruiting nowThis study tests a program called ADELANTE for Latinos with HIV whose virus is not well-controlled. Participants will either receive five sessions with a community health worker who helps solve problems, or five reminder phone calls. The goal is to see if the health worker progra…
Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Sep 24, 2026 00:00 UTC
-
New combo therapy aims to cure hepatitis b in over half of patients
Disease control Recruiting nowThis phase 2 trial tests a new combination of an anti-PD-1 antibody (a type of immunotherapy) plus standard antiviral drugs in 120 adults with chronic hepatitis B. The goal is to achieve a functional cure, where the virus is no longer active and patients can stop medication. The …
Phase 2 • Sponsor: The Second Affiliated Hospital of Chongqing Medical University • Aim: Disease control
Last updated Sep 24, 2026 00:00 UTC
-
New study offers free STI care to black youth in the deep south
Disease control Recruiting nowThis study provides free testing for chlamydia, gonorrhea, syphilis, and HIV to Black youth aged 15-26 in New Orleans. Those who test positive can get treatment at no cost and are encouraged to bring their partners. The goal is to reduce STI rates and health disparities in this c…
Sponsor: Tulane University • Aim: Disease control
Last updated Sep 23, 2026 00:00 UTC
-
Can donated immune cells calm the cytokine storm?
Disease control Recruiting nowResearchers are testing whether regulatory T cells taken from donated thymus tissue can control the dangerous immune overreaction that occurs in severe COVID-19 and acute respiratory distress syndrome (ARDS). The trial enrolls adults aged 18 to 65 who are hospitalized with acute …
Phase 1/2 • Sponsor: Hospital General Universitario Gregorio Marañon • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Prison program aims to alert partners of HIV risk
Disease control Recruiting nowThis study tests whether a program that helps incarcerated men with HIV notify their sex and drug-use partners about possible HIV exposure can increase testing and treatment. Participants can choose to tell partners themselves or have a trained notifier do it anonymously. The goa…
Sponsor: University of Illinois at Chicago • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Could a simpler HIV pill protect moms and babies?
Disease control Recruiting nowThis study will test a two-drug HIV pill (Dolutegravir/Lamivudine) in 210 pregnant women who have never taken HIV medication. The goal is to see if it controls the virus and prevents passing HIV to their babies. Participants will be compared to those on standard three-drug therap…
Phase 4 • Sponsor: Fundación Huésped • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Can a cancer drug flush out hidden HIV?
Disease control Recruiting nowResearchers are testing venetoclax, a drug that prompts certain cells to self-destruct, in people living with HIV who take antiretroviral therapy. The goal is to see if it can safely reduce the size of the latent HIV reservoir, the hidden pool of virus that persists despite treat…
Phase 1/2 • Sponsor: University of Aarhus • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Can donated plasma shield newborns from chikungunya brain damage?
Disease control Recruiting nowThis study tests whether giving newborns plasma from people who recently recovered from chikungunya can prevent brain swelling or damage. The trial will include 60 newborns whose mothers were infected around the time of birth. Half will receive the plasma transfusion, and their o…
Sponsor: Centre Hospitalier Universitaire de la Réunion • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New dengue drug could cut fever time and virus levels
Disease control Recruiting nowThis Phase 2 trial tests an experimental drug called EYU688 in 108 adults with dengue fever. Participants receive either the drug or a placebo to see if it lowers the amount of virus in the blood and shortens fever. The study is currently recruiting.
Phase 2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Can a new pill shorten dengue? trial tests resomelagon
Disease control Recruiting nowResearchers are testing whether an experimental drug called resomelagon can safely treat adults with dengue fever. The trial enrolls 120 adults who have had dengue symptoms for less than three and a half days. Participants receive either resomelagon or a placebo, along with stand…
Phase 2 • Sponsor: Federal University of Minas Gerais • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Blood test may let some throat cancer patients skip radiation after surgery
Disease control Recruiting nowThis study is for people with HPV-related throat cancer who have surgery to remove the tumor. Normally, some patients also get radiation afterward to lower the risk of cancer coming back. This trial tests whether it's safe to skip that radiation if a blood test two weeks after su…
Phase 2 • Sponsor: Medical University of South Carolina • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Higher dose of hepatitis b drug put to the test in damaged livers
Disease control Recruiting nowResearchers are testing whether a higher daily dose of the antiviral drug entecavir suppresses hepatitis B virus better than the standard lower dose in adults whose livers are already scarred and failing. The trial enrolls 48 people with hepatitis B and decompensated cirrhosis. P…
Phase 4 • Sponsor: Bangladesh Medical University • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Immune cell boost may help kids beat Post-Transplant viruses
Disease control Recruiting nowThis study tests whether adding immune cells from a family donor to standard antiviral drugs can help children and young adults clear stubborn adenovirus or cytomegalovirus infections after a stem cell transplant. About 69 participants will be randomly assigned to receive either …
Phase 3 • Sponsor: New York Medical College • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Could a Two-Drug HIV pill work for TB patients?
Disease control Recruiting nowThis study tests whether a two-drug HIV regimen (dolutegravir plus lamivudine) works as well as the standard three-drug regimen in people who also have tuberculosis and are on TB treatment. About 150 participants who have never taken HIV medication will be randomly assigned to on…
Phase 3 • Sponsor: Johns Hopkins University • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New hope for hepatitis delta: can switching drugs clear the virus?
Disease control Recruiting nowThis study tests whether switching from the current drug bulevirtide to a new drug called brelovitug can better control chronic hepatitis Delta. About 120 adults who have been on bulevirtide for at least 6 months will take brelovitug for 24 weeks. The main goal is to see if the v…
Phase 2/3 • Sponsor: Mirum Pharmaceuticals, Inc. • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Quick HIV meds may slash stigma for drug users
Disease control Recruiting nowThis study tests whether starting antiretroviral therapy within 7 days of an HIV diagnosis can reduce stigma and improve health outcomes for people who inject drugs. Researchers will develop a rapid-start strategy and pilot it with 135 participants at HIV clinics. The goal is to …
Sponsor: Yale University • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Can local clinics keep more people with HIV in care?
Disease control Recruiting nowResearchers in Peru are studying whether moving HIV care from specialized hospitals to primary health clinics helps more people stay in treatment and keep the virus suppressed. The trial combines two training programs, NIATx and Project ECHO, to give primary care staff the skills…
Sponsor: Yale University • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Could a gel stop genital warts from coming back?
Disease control Recruiting nowThis phase 2 trial tests whether applying a special gel (Geniwa gel) after laser removal can better treat recurrent genital warts and prevent them from returning. Adults who have had at least three laser treatments and still experience recurrences are eligible. Participants recei…
Phase 2 • Sponsor: KTH Biopharma • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Can early HIV treatment free infants from lifelong meds?
Disease control Recruiting nowThis study tests whether giving very early and intensive antiretroviral therapy, plus an antibody, can help infants with HIV achieve remission—meaning the virus stays undetectable even after stopping treatment. Researchers will enroll about 1,120 infants and follow them for safet…
Phase 1/2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
HIV-Positive livers for HIV-Positive patients: a new hope?
Disease control Recruiting nowThis study looks at whether people with HIV who need a liver transplant can safely receive a liver from a donor who also had HIV. Researchers will compare infections and cancer rates between those who get an HIV-positive donor liver and those who get an HIV-negative donor liver. …
Sponsor: Johns Hopkins University • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Heart hope: HIV-positive women may get better blood flow with common diabetes pills
Disease control Recruiting nowThis study looks at whether SGLT2 inhibitors, a class of diabetes and kidney drugs, can improve blood flow through the heart's small arteries in women with HIV who also have diabetes or chronic kidney disease. Eighty women aged 45-75 will be randomly assigned to health education …
Phase 2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Lab-Grown immune cells take on dangerous viruses in vulnerable patients
Disease control Recruiting nowThis study tests whether specially grown donor immune cells (called cytotoxic T lymphocytes) can safely and effectively control BK and JC virus infections in people with weakened immune systems, such as those with cancer, HIV, or organ transplants. About 100 participants will rec…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Killer virus turned against childhood brain cancer
Disease control Recruiting nowThis early-stage trial tests whether a specially engineered herpes virus (G207) is safe to inject directly into the brain tumors of children whose cancer has returned. Up to 24 children aged 3 to 21 will receive the virus, and some will also get a small dose of radiation to help …
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Supercharged donor cells take on viruses after transplant
Disease control Recruiting nowThis study tests whether specially grown donor immune cells (viral-specific T-cells) can safely treat viral infections that often occur after a stem cell transplant. These infections can be serious and sometimes don't respond to standard antiviral drugs. The approach aims to boos…
Phase 1/2 • Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Donor immune cells aim to fight virus in vulnerable patients
Disease control Recruiting nowThis early-stage trial tests whether specially grown donor T cells can safely treat adenovirus infections in people with weakened immune systems, such as cancer patients. The cells are designed to target and kill the virus. The study will check for side effects and see if the inf…
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Can a short course of hepatitis c drugs before kidney transplant prevent infection?
Disease control Recruiting nowThis study looks at the best time to give hepatitis C medication to people without HCV who receive a kidney from an HCV-positive donor. One group starts the drug just before transplant and takes it for only 2 weeks; the other starts after transplant and takes it for 12 weeks. The…
Sponsor: Johns Hopkins University • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New combo aims to cure hepatitis b in over half of patients
Disease control Recruiting nowThis phase 2 trial tests a combination of an anti-PD-1 antibody, interferon, and standard antiviral drugs in 120 adults with chronic hepatitis B. The goal is to boost the immune system to clear the virus and achieve a functional cure, where the virus stays under control without l…
Phase 2 • Sponsor: The Second Affiliated Hospital of Chongqing Medical University • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Can a shot and a vaccine free people with HIV from daily pills? early trial aims to find out.
Disease control Recruiting nowThis early-stage study tests whether giving two powerful antibodies along with a therapeutic HIV vaccine can help people with HIV control the virus after they stop their daily antiretroviral therapy. The trial enrolls 48 adults in Thailand who started HIV treatment very soon afte…
Phase 1 • Sponsor: Henry M. Jackson Foundation for the Advancement of Military Medicine • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Donor immune cells show promise against dangerous viruses in vulnerable patients
Disease control Recruiting nowThis study tests whether specially grown immune cells from an unrelated donor can safely treat viral infections in people with weakened immune systems, such as after a stem cell transplant. About 750 participants will receive these cells and be monitored for side effects like inf…
Phase 2 • Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Can donor cells stop viruses after transplant?
Disease control Recruiting nowThis study tests whether giving patients donor-derived immune cells (VSTs) on a regular schedule can prevent dangerous viral infections after a stem cell transplant. 180 participants will be randomly assigned to receive VSTs either on a fixed schedule or only when a virus is dete…
Phase 2 • Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Can a blister beetle extract banish common warts? phase 3 trial investigates
Disease control Recruiting nowThis Phase 3 trial tests YCANTH, a topical solution containing cantharidin (a substance from blister beetles), against a placebo for treating common warts. About 300 people aged 2 and older with at least one wart on their body (excluding certain areas) will receive either the act…
Phase 3 • Sponsor: Verrica Pharmaceuticals Inc. • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can a Same-Day HIV pill restart help patients get back on track?
Disease control Recruiting nowThis study looks at whether people with HIV who have stopped their medication for at least 12 weeks can safely restart treatment with a single daily pill (B/F/TAF) on the same day they return to care. About 200 adults will take part to see if this quick restart helps lower the vi…
Phase 4 • Sponsor: CAN Community Health • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
One spot, many warts: heat and peroxide may trigger a full clearance
Disease control Recruiting nowThis trial tests a two-part approach for viral warts: applying mild heat at 44°C to the largest wart and using a 3% hydrogen peroxide solution on all warts. The idea is that heating one lesion may rally the immune system to fight the virus elsewhere, while the peroxide works dire…
Sponsor: First Hospital of China Medical University • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Can a new pill shorten COVID-19 symptoms?
Disease control Recruiting nowThis phase 3 trial is testing whether the oral drug secutrelvir can help people with COVID-19 recover faster. The study involves about 1,200 nonhospitalized participants aged 12 to 75 who start treatment within 48 hours of symptom onset. Half will receive secutrelvir and half a p…
Phase 3 • Sponsor: Shionogi • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New pill takes on rare, stubborn lymphoma
Disease control Recruiting nowThis early-phase trial is testing an oral drug called VK-2019 in 30 adults with a type of lymphoma (DLBCL) that is linked to the Epstein-Barr virus and has not responded to at least two prior treatments. Participants take the drug daily in 28-day cycles at one of three dose level…
Phase 1 • Sponsor: Pierluigi Porcu • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New antibody cocktail aims to block HIV without daily pills
Disease control Recruiting nowThis early-stage trial is testing whether lab-made antibodies that target HIV are safe and how long they stay in the body. About 83 healthy adults without HIV will receive the antibodies by vein or under the skin, alone or in combination. The goal is to find the right dose and ch…
Phase 1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New antibody BNT351 enters first human trial for HIV
Disease control Recruiting nowThis early-stage study tests a new antibody called BNT351 in 67 adults, both with and without HIV. The goal is to check safety, how long the antibody stays in the blood, and whether it can lower HIV levels in people with the virus. It is a first step toward possibly controlling H…
Phase 1 • Sponsor: BioNTech SE • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Can a newer hepatitis b drug protect babies while being gentler on their bones?
Disease control Recruiting nowThis trial compares two antiviral drugs, tenofovir alafenamide (TAF) and tenofovir disoproxil fumarate (TDF), in pregnant women with high hepatitis B virus levels. The goal is to see if TAF can prevent passing the virus to the baby as effectively as TDF, but with fewer side effec…
Sponsor: Xingfei Pan • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
A new attack on Epstein-Barr fatigue: two capsules put to the test
Disease control Recruiting nowThis trial tests whether two experimental capsules, 2LEBV and 2LXFS, can reduce fatigue and other symptoms in people with an Epstein-Barr virus infection. Participants take one capsule daily for six months, either one of the study drugs or a placebo. The study measures changes in…
Phase 4 • Sponsor: Labo'Life • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
A pill that fights warts from the inside: trial puts immune-regulating capsule to the test
Disease control Recruiting nowThis trial tests whether a daily oral capsule called 2LVERU can clear common, flat, or plantar warts caused by HPV. Researchers compare the capsule against a placebo in 162 people aged 3 and older over 6 months. The main question is whether warts disappear completely by the end o…
Phase 4 • Sponsor: Labo'Life • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
A 20-Year-Old immune regulator faces its biggest test against cold sores
Disease control Recruiting nowThis trial tests whether 2LHERP, an immune regulator available for over 20 years, can reduce the number of cold sore outbreaks in adults who get at least six per year. Participants take one capsule daily for six months, then researchers compare outbreak rates over a year against …
Phase 4 • Sponsor: Labo'Life • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
A 20-Year-Old immune regulator faces its biggest test against HPV
Disease control Recruiting nowThis trial tests whether 2LPAPI, an immune regulator used for over 20 years, can help clear high-risk genital HPV infections faster than a placebo. Researchers will enroll 284 women aged 25 to 45 with a current high-risk HPV diagnosis. Participants receive either 2LPAPI or a plac…
Phase 4 • Sponsor: Labo'Life • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Gut bacteria pill may shield HIV patients from heart disease
Disease control Recruiting nowThis trial tests whether a daily probiotic pill can improve gut health and lower heart disease risk in 250 people living with HIV who drink heavily. Heavy drinking changes gut bacteria, which may raise inflammation and heart disease risk. Researchers will measure changes in gut b…
Phase 2 • Sponsor: Vanderbilt University Medical Center • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Can a shorter, targeted radiation course tame throat cancer?
Disease control Recruiting nowThis phase III trial compares a new, shorter radiation approach to the standard 7-week chemoradiation for patients with HPV-positive oropharynx cancer. The experimental treatment uses a precise, high-dose radiation boost to the tumor followed by a reduced-dose chemoradiation cour…
Phase 3 • Sponsor: Centre hospitalier de l'Université de Montréal (CHUM) • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Can a blue dye tame hepatitis b?
Disease control Recruiting nowThis pilot study tests whether methylene blue, a compound with antiviral properties in lab tests, can reduce hepatitis B virus levels in people with chronic infection. Participants take methylene blue capsules for up to 6 months, with the dose possibly increasing if the initial d…
Phase 2 • Sponsor: Fondazione Epatocentro Ticino • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
Smartphone therapy: could an app help men with HIV kick stimulants?
Disease control Recruiting nowThis study investigates whether a mobile app called reSET can help men who have sex with men, are living with HIV, and have a stimulant use disorder reduce their drug use and keep their HIV under control. Participants use the app for 12 weeks, completing modules on topics like ma…
Sponsor: University of Miami • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Could family clinics cure hepatitis c as well as specialists?
Disease control Recruiting nowThis trial tests whether treating hepatitis C in primary care clinics, with non-specialist doctors, works as well as the standard specialist care in Brazil. It also evaluates the use of rapid tests and self-testing to find more people with the infection. The goal is to see if a s…
Phase 4 • Sponsor: Oswaldo Cruz Foundation • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Immunotherapy combo may outperform chemo in rare lymphoma
Disease control Recruiting nowThis Phase 3 trial tests whether an immunotherapy-based regimen (sintilimab, pegaspargase, and anlotinib) works better than standard chemotherapy before a stem cell transplant in people with newly diagnosed, advanced extranodal NK/T-cell lymphoma. Participants are randomly assign…
Phase 3 • Sponsor: Rong Tao • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Can a new immune drug outsmart Hard-to-Treat tumors?
Disease control Recruiting nowThis trial tests an experimental drug called STAR0602, which is designed to help the immune system attack cancer cells. It is being studied in people with advanced solid tumors that have not responded to standard treatments. The drug is given alone or combined with chemotherapy, …
Phase 1/2 • Sponsor: Marengo Therapeutics, Inc. • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can peer mentors help stop HIV transmission from mother to child?
Disease control Recruiting nowThis study tests an enhanced Mentor Mother strategy, where trained peer counselors provide tailored support to pregnant and postpartum women living with HIV. The goal is to see if this approach can be successfully implemented and improve health outcomes, such as keeping mothers i…
Sponsor: Indiana University • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can antivirals tame a deadly Tick-Borne virus?
Disease control Recruiting nowThis trial tests whether two antiviral drugs, favipiravir and ribavirin, can help clear the virus faster in adults hospitalized with Crimean-Congo hemorrhagic fever (CCHF), a severe tick-borne infection. Participants will receive one of the drugs or optimized standard care, and r…
Phase 2 • Sponsor: Liverpool School of Tropical Medicine • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Sniffing your way back: does scent therapy rebuild COVID-Shattered smell?
Disease control Recruiting nowThis trial tests whether a 12-week smell training program can help people who lost their sense of smell after COVID-19. Participants will sniff four different scents twice daily, with one group using rose, orange, clove, and eucalyptus, and another using cheese, coffee, strawberr…
Sponsor: Université du Québec à Trois-Rivières • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Smart pill bottles and health coaches team up to tackle HIV in the deep south
Disease control Recruiting nowThis trial tests whether combining community health worker support with a smart pill bottle that tracks medication and sends reminders can improve HIV treatment adherence and viral suppression. The study enrolls 420 adults with HIV in Alabama, Louisiana, and Mississippi who have …
Sponsor: Columbia University • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Flu drug zanamivir tested against Dengue's deadliest complication
Disease control Recruiting nowThis pilot trial tests whether intravenous zanamivir, a drug already used for flu, can reduce vascular permeability — the dangerous blood vessel leakage that is the main cause of death in dengue fever. About 74 people with dengue and warning signs will receive either zanamivir or…
Phase 2 • Sponsor: George Washington University • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
New drug aims to tame severe viral lung infections
Disease control Recruiting nowThis study tests whether a daily pill called AP1189 can help hospitalized patients with breathing failure due to viruses like flu, RSV, or COVID-19. About 96 adults will receive either AP1189 or a placebo for 14 days, on top of usual care. The main goal is to see if the drug redu…
Phase 2 • Sponsor: SynAct Pharma Aps • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Can Long-Acting HIV shots outperform daily pills during lymphoma treatment?
Disease control Recruiting nowThis trial investigates whether long-acting injectable antiretroviral drugs can control HIV better than standard oral pills in adults with AIDS-related lymphoma who are also receiving chemotherapy. Participants will receive one of three HIV treatment strategies—oral pills alone, …
Sponsor: Shanghai Public Health Clinical Center • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
Pee test could revolutionize HIV treatment adherence
Disease control Recruiting nowThis trial tests whether a low-cost, point-of-care urine test can help people with HIV who are not virally suppressed stick to their antiretroviral therapy. Participants provide a urine sample that is immediately tested for the presence of the drug tenofovir. Based on the result,…
Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Could a common gout pill protect hearts in HIV?
Disease control Recruiting nowThis trial tests whether colchicine, an anti-inflammatory drug used for gout, can reduce inflammation in the coronary arteries of people with HIV who have high cardiovascular risk. Participants take either colchicine or a placebo daily for 96 weeks, and changes in artery inflamma…
Phase 2 • Sponsor: Instituto de Investigación Hospital Universitario La Paz • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Engineered virus targets Hard-to-Treat cancers from the inside
Disease control Recruiting nowThis study tests an experimental therapy called YH02, a genetically modified virus designed to infect and destroy cancer cells. It is given as an injection directly into tumors in people with advanced solid tumors (such as head and neck cancer, breast cancer, or melanoma) that ha…
Phase 2 • Sponsor: Tianjin First Central Hospital • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Could a simple app help pharmacists stop HIV?
Disease control Recruiting nowThis study tests whether a software program called PEPPI makes it easier for pharmacists to offer HIV prevention pills (PEP and PrEP) and for patients to get them. Pharmacists and patients use the software during their normal visits, and researchers compare how well the service w…
Sponsor: EMPOWERX INC • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Could a simpler Two-Drug HIV regimen be just as effective as three?
Disease control Recruiting nowThis trial tests whether a two-drug combination (darunavir/cobicistat plus lamivudine) works as well as a standard three-drug combination (darunavir/cobicistat plus tenofovir alafenamide/emtricitabine) in people with HIV whose virus is already suppressed. The study involves 78 ad…
Phase 4 • Sponsor: Instituto Mexicano del Seguro Social • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Self-Sampling could boost cervical cancer screening for women with HIV
Disease control Recruiting nowThis study tests a program to help women living with HIV in Ghana get screened for cervical cancer more easily. The program includes self-sampling kits, patient navigators, and training for healthcare providers. Researchers want to see if these tools increase screening rates and …
Sponsor: Baylor University • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Community health workers may be key to helping black patients with HIV achieve lasting viral control
Disease control Recruiting nowThis study tests whether community health workers (CHWs) can help Black people with poorly controlled HIV achieve long-term viral suppression. CHWs provide support through weekly phone calls, home visits, and clinic accompaniment for three months. The study enrolls 10 Black adult…
Sponsor: University of Miami • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Can 'Supercharged' donor cells beat viruses that drugs Can't?
Disease control Recruiting nowThis study tests whether giving patients special donor immune cells (called CD45RA-depleted DLI) can treat viral infections that persist after a stem cell transplant. The trial involves 30 participants who have not improved with standard antiviral drugs. Researchers will measure …
Phase 1/2 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Banked immune cells show promise against Life-Threatening viruses in transplant patients
Disease control Recruiting nowThis early-phase study tests whether specially trained immune cells from healthy donors can safely treat viral infections (EBV, CMV, adenovirus, BK virus) in patients who have had a stem cell transplant or certain CAR-T therapy. These infections can be life-threatening when the i…
Phase 1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New vaccine aims to tame chronic hepatitis b without daily pills
Disease control Recruiting nowThis study tests a therapeutic vaccine called TherVacB in 81 adults with chronic hepatitis B who are already on antiviral medication. The vaccine is given as a series of shots to boost the immune system and lower hepatitis B virus levels. The main goals are to check safety and se…
Phase 1/2 • Sponsor: Michael Hoelscher • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Can a standard HIV pill rescue those who got infected on Long-Acting PrEP?
Disease control Recruiting nowThis study tests a daily combination pill (TLD) as first-line HIV treatment for 100 people who became infected with HIV despite receiving long-acting cabotegravir PrEP in the past year. Researchers will check if the pill can suppress the virus to undetectable levels after 6 month…
Phase 4 • Sponsor: University of Witwatersrand, South Africa • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Immune cells take on BK virus in vulnerable transplant patients
Disease control Recruiting nowThis study tests whether specially grown immune cells (called cytotoxic T lymphocytes) can safely lower BK virus levels in 20 transplant patients with weakened immune systems. Participants have had a stem cell or kidney transplant and show signs of BK virus infection. The goal is…
Early phase 1 • Sponsor: Children's Hospital of Philadelphia • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Diet and exercise may ease long COVID symptoms in obese veterans
Disease control Recruiting nowThis study looks at how obesity affects recovery from post-COVID conditions in older Veterans. Researchers will test if a weight loss program with diet and exercise can reduce inflammation and improve physical function and quality of life. The study involves 150 Veterans, some wi…
Sponsor: VA Office of Research and Development • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Phone alerts and support groups aim to boost treatment success for dual epidemic
Disease control Recruiting nowThis study tests four approaches to help adults with drug-resistant tuberculosis and HIV stick to their treatments. Participants receive either standard care, counseling, phone reminders via a special pill bottle, or both counseling and reminders. The goal is to see which method …
Sponsor: Columbia University • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
Placental grafts show promise for stubborn diabetic foot sores
Disease control Recruiting nowThis study tests whether a special placental graft, used alongside standard wound care, helps close diabetic foot ulcers that won't heal on their own. About 350 adults with type 1 or 2 diabetes and a foot ulcer between 1 and 15 cm² will be randomly assigned to get the graft plus …
Phase 4 • Sponsor: Sequence LifeScience, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Can a smartphone app help young black women cut alcohol and prevent HIV?
Disease control Recruiting nowThis study tests whether a mobile app with a virtual group support feature can help young Black women (ages 18-30) who misuse alcohol reduce their drinking and risky sexual behavior, and increase their use of PrEP (a daily pill that prevents HIV). About 500 HIV-negative women in …
Sponsor: RTI International • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Could a common numbing drug help fight throat cancer?
Disease control Recruiting nowThis early-stage trial is testing whether injecting the local anesthetic lidocaine into HPV-related throat tumors before robotic surgery is safe and might help destroy more cancer cells. About 30 adults with HPV-positive oropharyngeal cancer will receive the injection during a ro…
Phase 1 • Sponsor: Ryan Carey • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Could a mailed saliva kit make oral HPV screening easier for people with HIV?
Diagnosis Recruiting nowPeople living with HIV face a higher risk of oral HPV infection and related throat cancer, but little is known about how the infection behaves in this group. This study asks whether saliva samples collected at home with a mail-delivered kit can detect oral HPV as reliably as samp…
Sponsor: University of California, San Francisco • Aim: Diagnosis
Last updated Oct 08, 2026 00:00 UTC
-
A mobile x-ray van with AI could spot TB before it spreads
Diagnosis Recruiting nowThis study tests a community-based screening strategy for tuberculosis (TB) in migrant communities in New York City. A mobile van offers digital chest X-rays with AI interpretation, along with TB symptom checks, blood tests for latent TB, and HIV testing. The goal is to see wheth…
Sponsor: Columbia University • Aim: Diagnosis
Last updated Oct 04, 2026 00:00 UTC
-
New rapid test could detect three infections at once
Diagnosis Recruiting nowThis study is testing a new rapid diagnostic device called TruPlex that can detect HIV, Hepatitis B, and Syphilis from a small blood sample. Researchers will enroll 1000 adults at risk for these infections to see how accurate and easy the test is to use in clinics and point-of-ca…
Sponsor: bioLytical Laboratories • Aim: Diagnosis
Last updated Oct 04, 2026 00:00 UTC
-
Could a simple urine test replace the pap smear for cervical cancer screening?
Diagnosis Recruiting nowThis study investigates whether urine samples can be used to screen for cervical cancer in women living with HIV. Researchers will compare the accuracy of urine HPV testing with self-collected and provider-collected samples to detect cervical precancer (CIN2 or worse). The goal i…
Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Diagnosis
Last updated Oct 02, 2026 00:00 UTC
-
Can HPV genotype predict who really needs closer cervical screening?
Diagnosis Recruiting nowResearchers in Sweden are analyzing health records from about 130,000 women who had a positive HPV test during cervical screening. The study asks whether the specific HPV genotype, how long the infection lasts, and whether past test results are available can predict the risk of c…
Sponsor: Karolinska Institutet • Aim: Diagnosis
Last updated Oct 02, 2026 00:00 UTC
-
15-Minute flu test could speed treatment in nursing homes
Diagnosis Recruiting nowResearchers test whether a rapid, 15-minute molecular flu test used directly in long-term care facilities helps older residents get diagnosed and treated faster than standard lab-based PCR testing. The trial enrolls residents aged 65 and older with symptoms like fever or low oxyg…
Sponsor: China Medical University Hospital • Aim: Diagnosis
Last updated Oct 01, 2026 00:00 UTC
-
A Finger-Prick could change the fight against hepatitis c
Diagnosis Recruiting nowThis large Australian study is testing whether offering a finger-stick point-of-care test for hepatitis C can increase diagnosis and treatment rates. Adults at risk for hepatitis C will be offered the rapid test at services they already use. Those who test positive for the virus …
Sponsor: Kirby Institute • Aim: Diagnosis
Last updated Sep 30, 2026 00:00 UTC
-
A simple finger prick could transform hepatitis c care
Diagnosis Recruiting nowThis large Australian study is testing whether offering finger-stick point-of-care testing for hepatitis C in community settings—like drug treatment clinics, homeless shelters, and prisons—can increase the number of people diagnosed and linked to treatment. The study will include…
Sponsor: Kirby Institute • Aim: Diagnosis
Last updated Sep 30, 2026 00:00 UTC
-
Blood test could outshine ultrasound in liver cancer screening
Diagnosis Recruiting nowThis phase IV trial will enroll 5,500 people with liver cirrhosis or chronic hepatitis B—conditions that raise liver cancer risk. Participants are randomly assigned to either standard ultrasound screening or a new blood test called GALAD, which measures three proteins. The goal i…
Phase 4 • Sponsor: University of Texas Southwestern Medical Center • Aim: Diagnosis
Last updated Sep 27, 2026 00:00 UTC
-
New AI-Powered swab test aims to spot viruses in minutes
Diagnosis Recruiting nowThis study tests a new technology called Pictura Bio that aims to detect respiratory viruses quickly and cheaply from nose or throat swabs. Researchers will collect samples from 1000 adults and children with suspected viral infections at a UK hospital. The data will be used to tr…
Sponsor: Portsmouth Hospitals NHS Trust • Aim: Diagnosis
Last updated Sep 19, 2026 00:00 UTC
-
Can a booklet and free tests get more people screened for two silent killers?
Diagnosis Recruiting nowResearchers test whether giving people education materials and free access to screening helps them get checked for colorectal cancer and hepatitis C. The trial enrolls adults ages 45 to 75 who receive care at community health centers and are not up to date on these screenings. Pa…
Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Diagnosis
Last updated Sep 18, 2026 00:00 UTC
-
Can a digital platform catch liver cancer sooner?
Diagnosis Recruiting nowResearchers are studying whether a digital management platform can help diagnose liver cancer at an earlier stage in people with chronic liver disease. The study enrolls adults aged 18 to 75 with conditions such as chronic hepatitis B. The platform tracks patients and guides stan…
Sponsor: Cai Qingxian • Aim: Diagnosis
Last updated Sep 17, 2026 00:00 UTC
-
Million-Person quest to catch a silent cancer early
Diagnosis Recruiting nowThis study aims to build a massive screening cohort of one million people to improve early detection of nasopharyngeal carcinoma, a cancer linked to Epstein-Barr virus (EBV). Participants aged 30 to 69 will provide blood, saliva, and nasal brush samples for EBV antibody and DNA t…
Sponsor: Ming-Yuan Chen • Aim: Diagnosis
Last updated Sep 03, 2026 00:00 UTC
-
Could Self-Sampling revolutionize cervical cancer screening?
Diagnosis Recruiting nowThis trial evaluates whether a new self-collection device, Mia by XytoTest, can be used effectively by people to collect their own vaginal samples for cervical cancer screening. The study compares the accuracy of these self-collected samples against clinician-collected samples fo…
Sponsor: Mel Mont Medical • Aim: Diagnosis
Last updated Aug 13, 2026 00:00 UTC
-
New blood test may sharpen diagnosis of autoimmune liver disease
Diagnosis Recruiting nowThis study evaluates whether a blood test measuring polyreactive immunoglobulin G (pIgG) can more accurately diagnose autoimmune hepatitis (AIH) and distinguish it from other liver conditions. Researchers will collect blood samples from 400 adults undergoing liver biopsy for susp…
Sponsor: Hannover Medical School • Aim: Diagnosis
Last updated Jul 17, 2026 00:00 UTC
-
Simple blood test aims to spot multiple cancers early
Diagnosis Recruiting nowThis study collects blood samples from healthy people, those with benign diseases, and cancer patients to develop a multi-analyte blood test. The test looks for DNA methylation markers that may indicate the presence of various cancers, especially liver cancer. Researchers aim to …
Sponsor: Helio Genomics • Aim: Diagnosis
Last updated Jul 12, 2026 00:00 UTC
-
New score could help doctors spot fungal pneumonia faster
Diagnosis Recruiting nowThis study aims to create and test a clinical prediction score called FUNGAL-P to help doctors identify fungal pneumonia early in adults who come to the hospital with pneumonia. Researchers will analyze medical records from past patients and then test the score on new patients to…
Sponsor: Azienda Ospedaliero-Universitaria Careggi • Aim: Diagnosis
Last updated Jul 04, 2026 00:00 UTC
-
Better CMV detection for IBD patients: which test works best?
Diagnosis Recruiting nowThis study looks at 200 adults with inflammatory bowel disease (IBD) who are hospitalized due to worsening symptoms. Researchers want to see if testing blood or stool for CMV (a common virus) is as accurate as the standard method of testing a tissue sample from the colon. The goa…
Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna • Aim: Diagnosis
Last updated Jun 27, 2026 14:00 UTC
-
Could a simple breath test replace nasal swabs for COVID-19?
Diagnosis Recruiting nowThis study is testing a new, portable breath test called eBAM-CoV to see if it can detect COVID-19 as accurately as the standard nasal swab test (RT-PCR). The breath test is less invasive and gives immediate results. Researchers will compare the two tests in 250 adults who have s…
Sponsor: Centre Hospitalier Universitaire de Nīmes • Aim: Diagnosis
Last updated Jun 27, 2026 12:37 UTC
-
New nasal swab test could spot hidden viruses in seniors
Diagnosis Recruiting nowThis study is testing whether measuring a natural immune marker called IFN-I in nasal swabs can help detect respiratory viral infections in older adults. Current PCR tests only look for a few viruses and can miss others or show old infections. The goal is to improve diagnosis, es…
Sponsor: Hospices Civils de Lyon • Aim: Diagnosis
Last updated Jun 27, 2026 12:36 UTC
-
Double probe heat therapy may slash cervical cancer risk in HIV-positive women
Prevention Recruiting nowThis study will test if using two heat probes instead of one can better prevent cervical cancer in 300 women with HIV in Zimbabwe. The standard single-probe treatment often fails in these women. The goal is to see if the two-probe method is safe, acceptable, and more effective at…
Sponsor: Fred Hutchinson Cancer Center • Aim: Prevention
Last updated Oct 20, 2026 06:00 UTC
-
Two probes better than one? new study aims to cut cervical cancer in women with HIV
Prevention Recruiting nowThis study will test whether using two heat probes instead of one to treat cervical precancer works better for women living with HIV. Researchers in Rwanda will enroll 300 women to see if the two-probe approach is safe, acceptable, and more effective at clearing HPV. The goal is …
Sponsor: Fred Hutchinson Cancer Center • Aim: Prevention
Last updated Oct 20, 2026 06:00 UTC
-
New injectable HIV prevention program aims to protect latine communities
Prevention Recruiting nowThis study tests a long-acting injectable PrEP (lenacapavir) program designed specifically for Latine gay, bisexual men and transgender women. Researchers want to see if offering the shots at community organizations helps more people stay on HIV prevention compared to standard cl…
Phase 4 • Sponsor: Duke University • Aim: Prevention
Last updated Oct 20, 2026 06:00 UTC
-
Could friendly bacteria in a gel stop HIV? new study begins
Prevention Recruiting nowThis early-stage study tests a vaginal gel containing specially modified bacteria that produce an anti-HIV drug. The goal is to see if it is safe for healthy women and whether it can be cleared with antibiotics. If successful, this could become a long-lasting, woman-controlled HI…
Phase 1 • Sponsor: Craig Cohen, MD, MPH • Aim: Prevention
Last updated Oct 18, 2026 00:00 UTC
-
New nasal spray aims to stop colds and flu before they start
Prevention Recruiting nowThis study tests an investigational nasal spray called INNA-051 to see if it can safely prevent or reduce the severity of viral respiratory infections like colds and flu. It involves 1100 healthy adults aged 18 to 45 who are at higher risk due to their living or work conditions. …
Phase 2 • Sponsor: ENA Respiratory Pty Ltd • Aim: Prevention
Last updated Oct 18, 2026 00:00 UTC
-
New family program aims to prevent multiple health crises in latino immigrant communities
Prevention Recruiting nowThis study tests a six-session program called SER Familia for Latino immigrant families with a parent and a child aged 12-17. The program, led by community health workers, aims to reduce stress from adapting to a new culture and build resilience. The goal is to prevent substance …
Sponsor: Duke University • Aim: Prevention
Last updated Oct 18, 2026 00:00 UTC
-
App and home delivery aim to keep youth HIV-free
Prevention Recruiting nowThis study tests a new way to help young people (ages 13-24) stick with PrEP, a medication that prevents HIV. Participants get PrEP delivered to a community spot (like home or a mobile van) and use a smartphone app for reminders and support. The goal is to see if this combo impro…
Sponsor: Westat • Aim: Prevention
Last updated Oct 18, 2026 00:00 UTC
-
Can a personal guide help more men stay on the HIV prevention pill?
Prevention Recruiting nowResearchers are testing whether a strengths-based patient navigation program helps men start and stay on PrEP, a daily pill that greatly lowers the risk of getting HIV. The trial enrolls 300 men who have sex with men and receive care at community health centers. Half receive the …
Sponsor: Brown University • Aim: Prevention
Last updated Oct 18, 2026 00:00 UTC
-
One-Shot flu prevention? new drug aims to protect High-Risk groups all season
Prevention Recruiting nowThis phase 3 trial is testing whether a single dose of CD388, a long-acting antiviral injection, can prevent the flu in 10,000 adults and teens at higher risk of complications. Participants receive either CD388 or a placebo and are monitored for flu-like illness over 24 weeks. Th…
Phase 3 • Sponsor: Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) • Aim: Prevention
Last updated Oct 17, 2026 00:00 UTC
-
Can a text message about vaccine choices boost COVID-19 shots?
Prevention Recruiting nowResearchers at Kaiser Permanente Southern California are testing whether reminder messages that highlight COVID-19 vaccine choices increase vaccination among adults at high risk of severe illness. The trial randomly assigns eligible members to receive either a standard reminder o…
Sponsor: Kaiser Permanente • Aim: Prevention
Last updated Oct 17, 2026 00:00 UTC
-
Can one shot boost omicron defenses for the most vulnerable?
Prevention Recruiting nowResearchers are testing a single dose of an omicron-based COVID-19 vaccine called Nuvaxovid in people aged 65 and older, and in people aged 12 to 64 who have a health condition that raises their risk of severe COVID-19. All participants received a COVID-19 vaccine at least 90 day…
Phase 4 • Sponsor: Sanofi • Aim: Prevention
Last updated Oct 17, 2026 00:00 UTC
-
Could a daily supplement keep the common cold at bay?
Prevention Recruiting nowThis trial tests whether a daily supplement called Immune X can help prevent common colds in healthy adults who often get upper respiratory infections. Over 16 weeks during winter, participants take either Immune X or a placebo and track any cold symptoms. The study compares how …
Sponsor: Givaudan France Naturals • Aim: Prevention
Last updated Oct 15, 2026 00:00 UTC
-
Bedside flu shot for heart patients: a simple strategy to save lives?
Prevention Recruiting nowThis trial tests whether offering a seasonal flu vaccine to heart patients while they are still in the hospital, along with active counseling, increases vaccination rates compared to counseling alone. The study enrolls adults hospitalized for acute coronary syndrome or heart fail…
Sponsor: Stephan Baldus • Aim: Prevention
Last updated Oct 15, 2026 00:00 UTC
-
New study combines app support and antibiotic after sex to fight HIV and STIs in youth
Prevention Recruiting nowThis study tests a mobile health program called PrEP Choice to help young people ages 13-24 start and stick with HIV prevention pills or shots. It also looks at whether taking the antibiotic doxycycline after sex (DoxyPEP) can prevent other sexually transmitted infections. About …
Sponsor: Westat • Aim: Prevention
Last updated Oct 11, 2026 00:00 UTC
-
Could a light device stop COVID and flu? new trial aims to find out.
Prevention Recruiting nowThis trial tests a handheld light device (RD-X19) to see if using it for 5 minutes every other day can prevent upper respiratory infections like COVID-19 and flu. It involves 130 military personnel and their families at a single base. Half will get the real device, half a sham de…
Sponsor: David Moss • Aim: Prevention
Last updated Oct 10, 2026 00:00 UTC
-
Can simple reminders and training boost HPV shots in rural teens?
Prevention Recruiting nowThis study tests different strategies to increase HPV vaccination among 9- to 12-year-olds in rural North Central Florida. Clinics will be randomly assigned to offer clinician training alone, training plus parent reminders, or all three including help accessing healthcare. Resear…
Sponsor: University of Florida • Aim: Prevention
Last updated Oct 10, 2026 00:00 UTC
-
Farming program aims to cut STI rates in kenyan teens
Prevention Recruiting nowThis study tests a program called Shamba Maisha that provides farming tools, training, and school gardens to families in Kenya. The goal is to reduce food insecurity and poverty, which are linked to higher STI and HIV risk in adolescent girls. Researchers will follow 900 girls an…
Sponsor: University of California, San Francisco • Aim: Prevention
Last updated Oct 10, 2026 00:00 UTC
-
Finger-Prick test could guide hepatitis b treatment in pregnancy
Prevention Recruiting nowPregnant women with hepatitis B can pass the virus to their babies during birth. To prevent this, guidelines recommend treating women with high levels of the virus using the drug tenofovir. However, many clinics in low-income countries cannot measure virus levels. This trial comp…
Sponsor: ANRS, Emerging Infectious Diseases • Aim: Prevention
Last updated Oct 10, 2026 00:00 UTC
-
Your Dentist's chair could become an HIV testing site
Prevention Recruiting nowResearchers at Columbia University are studying whether dental clinics can play a bigger role in HIV prevention and care. The trial compares two ways of running a dental practice: a standard model and an enhanced model that adds electronic prompts for HIV testing plus a care navi…
Sponsor: Columbia University • Aim: Prevention
Last updated Oct 09, 2026 00:00 UTC
-
One shot to stop RSV: landmark trial for indigenous kids
Prevention Recruiting nowThis study tests whether a single dose of nirsevimab, an antibody that targets RSV, can prevent respiratory infections in Aboriginal and Torres Strait Islander children aged 6 months. Around 1,000 children will be randomly assigned to receive either the antibody or standard care.…
Phase 4 • Sponsor: Menzies School of Health Research • Aim: Prevention
Last updated Oct 09, 2026 00:00 UTC
-
Peer mentors may help women stay HIV-Free – trial tests new approach
Prevention Recruiting nowThis trial tests whether a peer-led program that lets women choose and switch HIV prevention methods can increase consistent use compared to standard care. The program includes peer mentor support, HIV testing, access to PEP, and STI care. It enrolls HIV-negative women at elevate…
Sponsor: University of California, San Francisco • Aim: Prevention
Last updated Oct 08, 2026 00:00 UTC
-
New HIV prevention shot tested in real-world clinics
Prevention Recruiting nowThis study looks at how well people stick to a new HIV prevention shot called lenacapavir. About 3,000 people in the U.S. who want or need HIV prevention will take part. Researchers will track who stays on the shot and how it works in everyday clinic settings.
Sponsor: Gilead Sciences • Aim: Prevention
Last updated Oct 03, 2026 00:00 UTC
-
Can baby shots become a chance to stop HIV in mothers?
Prevention Recruiting nowResearchers are testing whether a program called the LINK model helps breastfeeding women in Malawi start and stay on HIV prevention medicine (PrEP). The program ties HIV testing and PrEP to infant vaccination visits, screens for HIV risk, involves male partners, and provides pee…
Sponsor: University of North Carolina, Chapel Hill • Aim: Prevention
Last updated Oct 02, 2026 00:00 UTC
-
Chikungunya vaccines face Real-World test in island outbreaks
Prevention Recruiting nowResearchers are studying how well two chikungunya vaccines, IXCHIQ and VIMKUNYA, prevent infection in adults during outbreaks on Réunion Island and in French Guiana. The study includes about 1,505 adults who are eligible for vaccination. By comparing infection rates between vacci…
Phase 4 • Sponsor: Centre Hospitalier Universitaire de la Réunion • Aim: Prevention
Last updated Sep 30, 2026 00:00 UTC
-
Can coaching teachers sustain HIV prevention in schools?
Prevention Recruiting nowThis study looks at how to keep an HIV prevention program running well in Bahamian schools over several years. Researchers will test different support strategies for teachers, like regular check-ins and mentorship. About 3,705 students and teachers will take part, and the study w…
Sponsor: University of Massachusetts, Worcester • Aim: Prevention
Last updated Sep 26, 2026 00:00 UTC
-
Can the MMR vaccine protect transplant kids? new study seeks answers
Prevention Recruiting nowThis study looks at whether the measles, mumps, and rubella (MMR) vaccine is safe and works well in children aged 1 to 17 who have had a heart transplant. About 60 children will receive the standard MMR vaccine and be monitored for side effects and immune response. The goal is to…
Phase 4 • Sponsor: Children's Mercy Hospital Kansas City • Aim: Prevention
Last updated Sep 26, 2026 00:00 UTC
-
Three flu shots, one question: which best awakens aging immune systems?
Prevention Recruiting nowResearchers compare three influenza vaccine formulations, standard dose, MF59 adjuvanted, and high dose, in adults aged 65 and older. The trial measures antibody levels before and after vaccination to see whether the formulations produce different immune responses. A younger refe…
Phase 4 • Sponsor: Korea University Guro Hospital • Aim: Prevention
Last updated Sep 26, 2026 00:00 UTC
-
Can a chatbot help end HIV? new study tests digital tool in black MSM
Prevention Recruiting nowThis study will test a chatbot designed to increase awareness and use of PrEP, a daily pill that prevents HIV, among Black men who have sex with men (MSM) in the Southern United States. About 145 participants will interact with the chatbot over 90 days, answering questions and re…
Sponsor: Yale University • Aim: Prevention
Last updated Sep 25, 2026 00:00 UTC
-
Choice of location may boost HIV prevention persistence
Prevention Recruiting nowThis study tests whether letting people choose where they get their follow-up HIV prevention injections (home, community, or clinic) helps them stick with the treatment. 400 HIV-negative adults in Massachusetts will receive the same-day injectable drug lenacapavir and be randomly…
Sponsor: Massachusetts General Hospital • Aim: Prevention
Last updated Sep 25, 2026 00:00 UTC
-
Can a Hands-On therapy supercharge the flu vaccine?
Prevention Recruiting nowThis study explores whether a type of hands-on therapy called osteopathic manipulation can improve how well the seasonal flu vaccine works in people who are more vulnerable to severe flu, including older adults and those with higher body weight. Participants will receive several …
Sponsor: Lake Erie College of Osteopathic Medicine • Aim: Prevention
Last updated Sep 25, 2026 00:00 UTC
-
Can picturing your future help you stay HIV-Free?
Prevention Recruiting nowResearchers are testing whether a behavioral program called Episodic Future Thinking can help gay and bisexual men and other sexual minority adults reduce methamphetamine use and risky sexual behavior while sticking with their HIV prevention medication, PrEP. The study enrolls 60…
Sponsor: The University of Texas Health Science Center at San Antonio • Aim: Prevention
Last updated Sep 25, 2026 00:00 UTC
-
Can legal aid and peer guides curb HIV risk in immigrant communities?
Prevention Recruiting nowResearchers are testing a program called Camino that pairs peer navigators with legal services for Latin American immigrants in Washington, DC, and the Oakland area. The program aims to reduce fear of seeking healthcare and connect people to HIV testing, prevention, and treatment…
Sponsor: American University • Aim: Prevention
Last updated Sep 24, 2026 00:00 UTC
-
New study aims to find best CMV prevention for kidney transplant patients
Prevention Recruiting nowThis study tests two different approaches to prevent cytomegalovirus (CMV) disease in adults who have received a kidney from a CMV-positive donor but are themselves CMV-negative. One group will take daily antiviral medicine for 200 days after transplant, while the other group wil…
Phase 3 • Sponsor: University of California, San Francisco • Aim: Prevention
Last updated Sep 23, 2026 00:00 UTC
-
New model aims to eliminate HIV transmission from mothers to infants in malawi
Prevention Recruiting nowThis study is testing a new approach called PAC-Man to help prevent HIV from passing from mothers to their babies. About 2,426 mothers and infants in Malawi will take part. The goal is to see if this model helps more babies get tested for HIV early and ensures mothers receive pro…
Sponsor: University of North Carolina, Chapel Hill • Aim: Prevention
Last updated Sep 20, 2026 00:00 UTC
-
Could STI testing be the key to getting more women on HIV prevention?
Prevention Recruiting nowThis study in Uganda tests whether adding lab tests for common sexually transmitted infections (STIs) to standard HIV risk screening helps more women start and stick with PrEP, a daily pill that prevents HIV. About 4,500 HIV-negative women aged 15-39 will be randomly assigned to …
Sponsor: Johns Hopkins University • Aim: Prevention
Last updated Sep 20, 2026 00:00 UTC
-
Monthly HIV prevention pill could replace daily dose
Prevention Recruiting nowThis phase 3 trial tests MK-8527, a once-monthly oral pill, to prevent HIV-1 infection in women. About 4580 HIV-negative women will take either MK-8527 monthly or a daily PrEP pill (Truvada) to see which works better and is safer. The goal is to offer a more convenient prevention…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Prevention
Last updated Sep 20, 2026 00:00 UTC
-
Can a Three-Session couples program cut drug use and HIV risk?
Prevention Recruiting nowResearchers are testing whether a three-session couples motivational interviewing program helps male couples reduce illicit drug use and behaviors that raise HIV transmission risk. The trial enrolls 360 male couples where at least one partner is HIV negative and at least one has …
Sponsor: Hunter College of City University of New York • Aim: Prevention
Last updated Sep 19, 2026 00:00 UTC
-
Plastic dome over Patients' heads tested as airborne germ barrier
Prevention Recruiting nowResearchers are testing a clear plastic dome placed over a patient's head during surgery to see if it can stop the spread of airborne germs in hospitals. The trial enrolls 80 adults having elective surgery that requires a breathing tube. Participants are randomly assigned to have…
Sponsor: IWK Health Centre • Aim: Prevention
Last updated Sep 18, 2026 00:00 UTC
-
Can an HPV shot stop vulvar lesions from coming back?
Prevention Recruiting nowWomen treated for vulvar high-grade squamous intraepithelial lesion (vHSIL), a precancerous condition linked to HPV, often see it return. This trial tests whether giving the Gardasil 9 HPV vaccine alongside standard treatment (surgery, laser, or imiquimod) can lower that recurren…
Phase 4 • Sponsor: Erasmus Medical Center • Aim: Prevention
Last updated Sep 17, 2026 00:00 UTC
-
Could 2 HPV vaccine doses be enough for women 27-45? new trial aims to find out.
Prevention Recruiting nowThis study compares the immune response from 2 doses versus the standard 3 doses of the HPV vaccine in women aged 27-45. About 618 participants will be randomly assigned to receive either 2 or 3 doses, and their antibody levels will be checked over 12 months. If 2 doses prove non…
Phase 4 • Sponsor: The University of Texas Medical Branch, Galveston • Aim: Prevention
Last updated Sep 17, 2026 00:00 UTC
-
Training police to refer, not arrest, could curb Drug-Related harm
Prevention Recruiting nowThis trial tests a police education program called SHIELD 2.0 in nine counties in Appalachian Kentucky. The program trains local behavioral health workers to teach police how to refer people who use drugs to treatment and social services instead of arresting them for low-level po…
Sponsor: Johns Hopkins Bloomberg School of Public Health • Aim: Prevention
Last updated Sep 13, 2026 00:00 UTC
-
Prisons as HIV prevention hubs: can opioid treatment reach more people behind bars?
Prevention Recruiting nowResearchers at Yale University are studying how to expand opioid agonist therapy (OAT) in prisons and probation systems in Tajikistan, Kyrgyzstan, Moldova, and Georgia. OAT uses medicines like methadone or buprenorphine to treat opioid dependence and can lower HIV transmission am…
Sponsor: Yale University • Aim: Prevention
Last updated Sep 12, 2026 00:00 UTC
-
New program aims to boost HIV prevention in pregnant women
Prevention Recruiting nowThis study tests a program called TENDAI4PrEP, which uses problem-solving techniques to help pregnant women in Zimbabwe take PrEP, a daily pill that prevents HIV. The program also involves their partners and healthcare providers. Researchers will enroll 132 HIV-negative pregnant …
Sponsor: Massachusetts General Hospital • Aim: Prevention
Last updated Sep 12, 2026 00:00 UTC
-
New antibody trial aims to block severe COVID-19
Prevention Recruiting nowThis early-stage study is testing an experimental antibody called MDX2301 to see if it can help prevent severe COVID-19 in healthy adults and those at higher risk. About 80 participants will receive either the antibody or a placebo, given as an injection or infusion. The main goa…
Phase 1 • Sponsor: ModeX Therapeutics, An OPKO Health Company • Aim: Prevention
Last updated Sep 12, 2026 00:00 UTC
-
Can virtual reality curb substance use and HIV in traumatized youth?
Prevention Recruiting nowThis study is developing and testing a virtual reality tool to help young people aged 15-30 who have experienced trauma and are at risk for substance use and HIV. The goal is to see if the tool can reduce substance use and risky behaviors. Researchers are recruiting young men who…
Sponsor: Medical University of South Carolina • Aim: Prevention
Last updated Sep 11, 2026 00:00 UTC
-
One shot for boys could slash HPV in tanzania
Prevention Recruiting nowThis study in Tanzania tests whether giving boys a single dose of the HPV vaccine (Gardasil) can lower HPV infections in the community. Over 10,000 participants in 26 communities will be split: some communities vaccinate only girls (as usual), while others also vaccinate boys age…
Phase 4 • Sponsor: London School of Hygiene and Tropical Medicine • Aim: Prevention
Last updated Sep 10, 2026 00:00 UTC
-
New tool aims to boost HIV prevention in Women's health clinics
Prevention Recruiting nowThis study tests a decision aid that helps women in sexual and reproductive health clinics decide whether to take PrEP, a daily pill that prevents HIV. The tool will be used during counseling visits. Researchers will see if it increases PrEP use and if it's practical for clinics.…
Phase 2 • Sponsor: Yale University • Aim: Prevention
Last updated Sep 06, 2026 00:00 UTC
-
Shingles sufferers: could this pill stop your pain from becoming chronic?
Prevention Recruiting nowThis study tests whether the oral medication venlafaxine, typically used for depression, can prevent postherpetic neuralgia—a persistent nerve pain that often follows a shingles rash. Researchers will enroll 832 adults who have had a shingles rash for less than 30 days and are ex…
Sponsor: Beijing Tiantan Hospital • Aim: Prevention
Last updated Sep 04, 2026 00:00 UTC
-
Can a Two-Pill HIV prevention strategy outsmart the virus?
Prevention Recruiting nowThis Phase 3 trial tests whether taking HIV prevention pills only around the time of sex can reduce the risk of HIV infection in men who have sex with men. Participants take either TAF/FTC or TDF/FTC, starting with a dose 2 to 24 hours before sex and another dose a day later. The…
Phase 3 • Sponsor: ANRS, Emerging Infectious Diseases • Aim: Prevention
Last updated Sep 04, 2026 00:00 UTC
-
Jail-Based program aims to cut HIV risk after release
Prevention Recruiting nowThis study tests a program in the Dallas County Jail that identifies people at high risk for HIV and offers them testing and education about PrEP, a daily pill that prevents HIV. A patient navigator helps interested individuals connect with PrEP providers after they are released.…
Sponsor: University of Texas Southwestern Medical Center • Aim: Prevention
Last updated Sep 04, 2026 00:00 UTC
-
Can a smartphone app break the stigma barrier to HIV prevention?
Prevention Recruiting nowThis study is testing a mobile app designed to help young Thai adults (ages 18-29) overcome stigma and start or stick with HIV prevention pills (PrEP). The app uses motivational interviewing and tailored content delivered over four sessions. Researchers will enroll 154 participan…
Sponsor: University of Massachusetts, Worcester • Aim: Prevention
Last updated Sep 02, 2026 00:00 UTC
-
A new strategy aims to close the HIV prevention gap for black gay men
Prevention Recruiting nowThis study tests a combination of programs to help Black gay, bisexual, and same-gender-loving men in the New York City area get tested for HIV and start taking PrEP, a daily pill that prevents HIV. Participants receive one or more of the following: a 3-session empowerment worksh…
Sponsor: Columbia University • Aim: Prevention
Last updated Sep 02, 2026 00:00 UTC
-
Barbershops and laundromats become frontline defense against HIV
Prevention Recruiting nowThis trial tests a program called the Five Point Initiative, which brings HIV testing, PrEP education and prescriptions, and condoms to everyday spots like barbershops, salons, and corner stores in predominantly Black communities in Miami. Researchers want to see if this approach…
Sponsor: University of Miami • Aim: Prevention
Last updated Aug 30, 2026 00:00 UTC
-
Emergency rooms may become a frontline for HIV prevention in teens
Prevention Recruiting nowThis trial tests three ways to screen adolescents and young adults for HIV in emergency departments: targeted screening based on risk, universal opt-in screening offered to everyone, and universal opt-out screening where testing is done unless declined. The goal is to see which a…
Sponsor: Westat • Aim: Prevention
Last updated Aug 19, 2026 00:00 UTC
-
Choice may boost HIV prevention: a trial tests offering multiple PrEP options to young women in kenya
Prevention Recruiting nowThis trial tests whether offering a menu of HIV prevention options — including daily pills and a vaginal ring — helps more young women aged 18–30 start and continue using PrEP. About 1,400 women seeking reproductive health services at clinics in Kenya will be offered either stand…
Phase 4 • Sponsor: University of Alabama at Birmingham • Aim: Prevention
Last updated Jul 24, 2026 00:00 UTC
-
Choice of Long-Acting HIV prevention could transform care for young people in rural south africa
Prevention Recruiting nowThis trial tests whether offering young people aged 15-30 in rural South Africa a choice of long-acting HIV prevention methods—such as a two-monthly injection or a vaginal ring—alongside standard daily pills and emergency prevention, increases how many start and stay on preventio…
Phase 3 • Sponsor: Africa Health Research Institute • Aim: Prevention
Last updated Jul 11, 2026 00:00 UTC
-
Can a phone app help women at risk of HIV start PrEP?
Prevention Recruiting nowThis study tests a mobile health program called WINGS+PrEP for women who have experienced heavy drinking, partner violence, and involvement with the criminal legal system. The program provides information about PrEP (a daily pill that prevents HIV) and offers support sessions. Re…
Sponsor: Columbia University • Aim: Prevention
Last updated Jun 27, 2026 14:01 UTC
-
HIV counselors lead new push to offer prevention pills at family planning visits
Prevention Recruiting nowThis study tests a new way to offer HIV prevention pills (PrEP) to people visiting family planning clinics in Kenya. Instead of requiring a separate appointment, HIV counselors will provide PrEP screening and prescriptions right at the family planning visit. The goal is to see if…
Sponsor: University of Washington • Aim: Prevention
Last updated Jun 27, 2026 14:00 UTC
-
New study aims to boost HIV prevention in people who inject drugs
Prevention Recruiting nowThis study tests four different approaches to help people who inject drugs remember and stick with their daily HIV prevention pill (PrEP). Researchers will enroll 256 adults who are newly on medication for opioid use disorder and have started PrEP. The goal is to see which method…
Phase 4 • Sponsor: University of Connecticut • Aim: Prevention
Last updated Jun 27, 2026 14:00 UTC
-
STI tests boost HIV prevention in pregnant women
Prevention Recruiting nowThis study in Botswana tests whether offering sexually transmitted infection (STI) testing alongside HIV prevention medication (PrEP) helps more pregnant women start and continue using PrEP. About 600 pregnant women without HIV will be split into two groups: one gets standard car…
Phase 3 • Sponsor: Botswana Harvard AIDS Institute Partnership • Aim: Prevention
Last updated Jun 27, 2026 13:07 UTC
-
At-Home HPV tests could boost cervical cancer screening in border communities
Prevention Recruiting nowThis study tests whether at-home HPV self-sampling (using urine or a vaginal swab) can help more people get screened for cervical cancer compared to the traditional in-clinic Pap smear. About 735 Latinx individuals aged 30-65 who haven't had a Pap test in at least three years wil…
Sponsor: University of Texas at Austin • Aim: Prevention
Last updated Jun 27, 2026 13:06 UTC
-
Baltimore study enlists peers to fight HIV and overdose among drug users
Prevention Recruiting nowThis pilot study tests whether a peer-driven program can help people who inject drugs in Baltimore reduce their risk of HIV, hepatitis C, and overdose. Researchers will identify high-risk injection settings and train peers to promote safer practices, like carrying naloxone and av…
Sponsor: Johns Hopkins Bloomberg School of Public Health • Aim: Prevention
Last updated Jun 27, 2026 12:37 UTC
-
New pill aims to shorten COPD Flare-Ups from common cold
Symptom relief Recruiting nowThis study tests an oral drug called vapendavir in 180 adults with COPD who catch a rhinovirus (common cold). The goal is to see if it can reduce the severity and length of breathing symptoms compared to a placebo. Participants are randomly assigned to one of two doses or a place…
Phase 2 • Sponsor: Altesa Biosciences, Inc. • Aim: Symptom relief
Last updated Oct 18, 2026 00:00 UTC
-
Can mild electric currents ease long COVID's lingering pain?
Symptom relief Recruiting nowResearchers are testing transcranial direct current stimulation (tDCS), a non-invasive technique that applies weak electrical currents to the scalp, in people with persistent COVID who have headaches, migraines, and chronic body pain. The study enrolls about 87 participants aged …
Sponsor: Fundación Universidad Católica de Valencia San Vicente Mártir • Aim: Symptom relief
Last updated Oct 17, 2026 00:00 UTC
-
Could old drugs beat long COVID? new trial aims to find out
Symptom relief Recruiting nowThis Phase 3 trial tests two repurposed drugs—upadacitinib and pirfenidone—against a placebo in 348 adults with Long COVID. Participants from six countries will take the drugs for three months to see if they ease symptoms like fatigue, breathing trouble, memory issues, muscle pai…
Phase 3 • Sponsor: Douglas D. Fraser • Aim: Symptom relief
Last updated Oct 08, 2026 00:00 UTC
-
Can a Stress-Reduction program help protect hearts in women with HIV?
Symptom relief Recruiting nowWomen living with HIV face two to four times the risk of heart disease compared with women without HIV, and those in the Southern US are especially affected. Researchers at the University of Alabama at Birmingham are adapting an 8-week stress management program that uses meditati…
Sponsor: University of Alabama at Birmingham • Aim: Symptom relief
Last updated Sep 30, 2026 00:00 UTC
-
VR headsets offer new hope for pandemic PTSD
Symptom relief Recruiting nowThis study tests whether virtual reality (VR) can help healthcare workers and COVID-19 patients with posttraumatic stress disorder (PTSD). Participants will use VR headsets during 10 therapy sessions over 5 weeks to safely revisit and overcome traumatic memories. The goal is to s…
Early phase 1 • Sponsor: Weill Medical College of Cornell University • Aim: Symptom relief
Last updated Sep 18, 2026 00:00 UTC
-
Tai chi via zoom tested as depression remedy for older HIV patients
Symptom relief Recruiting nowThis study tests whether doing tai chi/qigong over Zoom twice a week for 12 weeks can reduce depressive symptoms in people aged 50-75 living with HIV. About 326 participants will be randomly assigned to either tai chi or a health education class. Researchers will track mood, hear…
Sponsor: Florida International University • Aim: Symptom relief
Last updated Sep 18, 2026 00:00 UTC
-
New program aims to help HIV/TB patients kick the habit
Symptom relief Recruiting nowThis study is testing a new program called QUIT-AD to help people living with HIV or tuberculosis (TB) in Cape Town, South Africa, quit smoking. The program combines proven methods to support smoking cessation and improve HIV/TB treatment results. Researchers will enroll 86 daily…
Sponsor: Massachusetts General Hospital • Aim: Symptom relief
Last updated Sep 11, 2026 00:00 UTC
-
New study tests if happiness skills can curb stimulant use in HIV patients
Symptom relief Recruiting nowThis study tests whether a 5-session online program teaching positive thinking skills can help people with HIV who use stimulants. Researchers want to see if it reduces stimulant use and depression by changing brain and immune function. 189 participants will be followed for 3 mon…
Sponsor: Wake Forest University Health Sciences • Aim: Symptom relief
Last updated Sep 05, 2026 00:00 UTC
-
Peer support may lift the cloud of loneliness for older gay men with HIV
Symptom relief Recruiting nowThis study tests a 10-session peer-led program called Bridge to Belonging, designed to reduce loneliness and depression in older gay and bisexual men living with HIV. The program uses group sessions to build social skills and connect participants with LGBTQ+-affirming community s…
Sponsor: Fenway Community Health • Aim: Symptom relief
Last updated Aug 15, 2026 00:00 UTC
-
New Triple-Action pill takes on cold and flu symptoms
Symptom relief Recruiting nowThis study tests a new pill containing three ingredients (dipyrone, caffeine, and chlorpheniramine) to see if it works as well as a standard cold medicine for relieving stuffy nose and other cold and flu symptoms. About 620 adults with early cold or flu symptoms will take either …
Phase 3 • Sponsor: Brainfarma Industria Química e Farmacêutica S/A • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
New therapy aims to ease PTSD in HIV patients
Symptom relief Recruiting nowThis study is testing a type of talk therapy for people who have both HIV and PTSD. The therapy helps people understand how trauma affects their emotions and relationships. The goal is to see if this therapy is helpful and acceptable for this group. About 20 adults with HIV and P…
Sponsor: Montefiore Medical Center • Aim: Symptom relief
Last updated Jun 27, 2026 13:06 UTC
-
Why do some children develop severe inflammation after COVID-19? gene study investigates
Knowledge-focused Recruiting nowResearchers are investigating the genetic and immune factors that make some children develop multisystem inflammatory syndrome (MIS-C) after a COVID-19 infection. The study enrolls children with MIS-C or Kawasaki disease and their family members. Scientists will collect clinical …
Sponsor: Istituto Giannina Gaslini • Aim: Knowledge-focused
Last updated Oct 20, 2026 06:00 UTC
-
Does oktoberfest fuel the spread of respiratory viruses?
Knowledge-focused Recruiting nowThe MunichFlu study investigates whether attending the Munich Oktoberfest, one of the world's largest mass gatherings, is linked to respiratory viral infections. Researchers recruit adults at the festival and follow up one to two weeks later with an online questionnaire about sym…
Sponsor: LMU Klinikum • Aim: Knowledge-focused
Last updated Oct 20, 2026 06:00 UTC
-
Can your nose predict brain health? new study tests smell and choices in HIV and addiction
Knowledge-focused Recruiting nowThis study looks at how HIV and substance use disorder (SUD) affect the sense of smell and decision-making. Researchers will test 120 adults aged 18–65, including people with HIV, SUD, both, or neither. Participants will complete smell tests and computer tasks over two visits, an…
Sponsor: National Institute on Drug Abuse (NIDA) • Aim: Knowledge-focused
Last updated Oct 20, 2026 06:00 UTC
-
HIV study seeks volunteers for Long-Term monitoring
Knowledge-focused Recruiting nowThis study tracks the health of people with HIV over time to learn more about the infection and related conditions. It is for adults 18 and older in the Washington, D.C., area who have or may have HIV. Participants visit the clinic every few months for check-ups and blood tests, …
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Oct 18, 2026 00:00 UTC
-
Healthy volunteers willingly catch the flu for science
Knowledge-focused Recruiting nowThis study aims to find the safest and most effective dose of a specific flu virus to give to healthy adults in a controlled setting. About 90 volunteers aged 18 to 55 will be exposed to the virus or a placebo and closely monitored. The goal is to create a reliable model for test…
Phase 1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Oct 18, 2026 00:00 UTC
-
Scientists seek tissue samples to unlock HIV and cancer mysteries
Knowledge-focused Recruiting nowThis study collects blood, bone marrow, and tissue samples from people with HIV, KSHV, or certain cancers to help researchers learn more about these diseases. Participants must be 18 or older and may have HIV, KSHV, or related conditions. No treatment is given; the goal is to gat…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Oct 18, 2026 00:00 UTC
-
Cancer samples sought to unlock treatment secrets
Knowledge-focused Recruiting nowThis study collects blood, bone marrow, and tumor samples from 500 adults with cancer or pre-cancerous conditions. Researchers will use these samples to learn more about how cancers behave and why some respond differently to treatments. Participants provide samples over time and …
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Oct 18, 2026 00:00 UTC
-
Scientists seek samples to build better Cancer-Killing drugs
Knowledge-focused Recruiting nowThis study collects blood, urine, bone marrow, and tumor samples from people with hairy cell leukemia and other blood cancers, as well as from healthy volunteers. Researchers will use these samples to study the diseases and develop new treatments called immunotoxins, which use an…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Oct 18, 2026 00:00 UTC
-
Scientists probe HIV's secret hiding spots in uganda
Knowledge-focused Recruiting nowThis study looks at HIV that stays hidden in the body even when the virus is under control. Researchers will measure the 'latent HIV reservoir' in 130 Ugandans with HIV and compare it to similar groups in the US. Participants give blood samples and answer health questions. No new…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Oct 18, 2026 00:00 UTC
-
Scientists hunt for genetic clues in Virus-Linked cancers
Knowledge-focused Recruiting nowThis study collects tissue and blood samples from adults with HIV, other immune disorders, or cancers thought to be caused by viruses. Researchers will compare genes in cancer tissue to normal tissue to find genetic changes that drive these cancers. The goal is to better understa…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Oct 18, 2026 00:00 UTC
-
Scientists collect samples to unlock secrets of lymphoid cancers
Knowledge-focused Recruiting nowThis study collects blood, urine, bone marrow, and tissue samples from over 1,200 adults with lymphoid cancers or precancerous conditions. The goal is to help researchers better understand cancer biology, which may lead to new methods for diagnosing or treating these diseases. No…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Oct 18, 2026 00:00 UTC
-
Scientists hunt for genetic clues to severe viral infections
Knowledge-focused Recruiting nowThis study looks at people who have had unusually severe or long-lasting viral infections, like serious cases of herpes, HPV, or the flu. Researchers want to find out if these people have hidden immune system or genetic problems that make them more vulnerable. Up to 600 participa…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Oct 18, 2026 00:00 UTC
-
A single shot that lasts: researchers test Long-Acting drug in healthy volunteers
Knowledge-focused Recruiting nowResearchers are testing an experimental long-acting injectable drug called S-892216-LAI in healthy adults. The trial measures how safe and tolerable the drug is, and how the body absorbs and clears it after one or more doses. Participants receive either the drug or a saline place…
Phase 1 • Sponsor: Shionogi • Aim: Knowledge-focused
Last updated Oct 18, 2026 00:00 UTC
-
Scientists dig deeper: HIV study probes hidden viral reservoirs in lymph nodes
Knowledge-focused Recruiting nowThis study aims to understand how HIV behaves differently in the blood compared to lymph nodes and bone marrow. Researchers will take samples from 400 people living with HIV and some without HIV to measure virus levels and immune system changes. The goal is to learn more about wh…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Oct 18, 2026 00:00 UTC
-
Scientists dive deep into HIV immune cells to unlock secrets of early treatment
Knowledge-focused Recruiting nowThis study collects white blood cells from HIV patients through a process called leukapheresis to examine how the immune system responds to early treatment. Researchers aim to enroll 60 adults—30 with early HIV and 30 with chronic HIV—who are not yet on antiretroviral therapy. Pa…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Oct 18, 2026 00:00 UTC
-
Scientists hunt for immune secrets behind HIV control
Knowledge-focused Recruiting nowThis study collects white blood cells and plasma from 400 people with HIV, including rare 'non-progressors' who control the virus without medication. Researchers will analyze immune responses and genetic markers to understand what makes these individuals special. The goal is to u…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Oct 18, 2026 00:00 UTC
-
Scientists launch Long-Term study to unravel mysterious immune condition
Knowledge-focused Recruiting nowThis study follows 950 people with idiopathic CD4+ lymphocytopenia (ICL), a rare condition where low CD4+ white blood cells raise infection risk. Researchers will track participants for up to 10 years, collecting medical history, blood samples, and infection data. The goal is to …
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Oct 18, 2026 00:00 UTC
-
Scientists launch Decade-Long watch on kaposi sarcoma
Knowledge-focused Recruiting nowThis study follows 150 adults with Kaposi sarcoma (KS) for up to 10 years to learn how the disease behaves, why it comes back, and how it affects the immune system and organs. Participants will have regular check-ups, scans, and biopsies, but no new treatments are being tested. T…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Oct 18, 2026 00:00 UTC
-
NIH launches major study to unravel mysteries of long COVID recovery
Knowledge-focused Recruiting nowThis study follows 1,590 adults who have had COVID-19 to track their symptoms and recovery over three years. Participants complete phone interviews and online surveys every three months. The goal is to describe the range of recovery experiences and identify factors that lead to p…
Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) • Aim: Knowledge-focused
Last updated Oct 17, 2026 00:00 UTC
-
New study checks if HIV prevention shots and contraceptives clash
Knowledge-focused Recruiting nowThis study looks at how a long-acting injectable HIV prevention drug (CAB-LA) and hormonal birth control methods (like the shot or implant) affect each other in women. About 105 women who already use CAB-LA or no HIV prevention will join groups based on their contraceptive choice…
Sponsor: University of Alabama at Birmingham • Aim: Knowledge-focused
Last updated Oct 16, 2026 00:00 UTC
-
New brain scans may uncover hidden HIV damage
Knowledge-focused Recruiting nowThis study uses special PET scans to measure brain synapse density in people with HIV who are on effective treatment. Researchers want to understand why some still develop thinking or memory problems. They will compare 70 participants (with and without HIV) over two years using b…
Phase 1/2 • Sponsor: Yale University • Aim: Knowledge-focused
Last updated Oct 16, 2026 00:00 UTC
-
Blood test may help HIV patients cut down on drinking
Knowledge-focused Recruiting nowThis study looks at whether sharing results from a blood test that shows recent alcohol use can help people with HIV drink less. Researchers will enroll 80 people in Uganda who drink heavily. Half will get standard counseling plus their blood test results, and half will get couns…
Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated Oct 16, 2026 00:00 UTC
-
HIV memory mystery: even controlled virus may harm the brain
Knowledge-focused Recruiting nowThis study looks at why some people with HIV who have very low virus levels in their blood still develop thinking and memory problems. Researchers will follow 1,150 participants—including healthy volunteers—for up to 10 years, using brain scans, blood tests, and spinal fluid samp…
Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) • Aim: Knowledge-focused
Last updated Oct 15, 2026 00:00 UTC
-
Microvideos aim to boost HPV shots in young cancer survivors
Knowledge-focused Recruiting nowThis study tests whether short educational videos can help young adults who survived childhood cancer learn about and get the HPV vaccine. The researchers will enroll 55 survivors aged 18-26 who haven't finished the vaccine series. Participants will watch the videos on Facebook a…
Sponsor: University of Utah • Aim: Knowledge-focused
Last updated Oct 15, 2026 00:00 UTC
-
Scientists track rare genetic disorder to unlock its secrets
Knowledge-focused Recruiting nowThis study follows 600 people with GATA2 deficiency, a genetic disorder affecting the immune system and other body systems. Researchers aim to understand the full range of health problems it causes and why it affects people differently. Participants will have yearly check-ups for…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Oct 15, 2026 00:00 UTC
-
NIH launches massive study to unlock HIV's secrets through blood
Knowledge-focused Recruiting nowThis study aims to learn more about how HIV infects cells and affects the immune system by collecting blood samples from up to 2,419 adults, both with and without HIV. Researchers will analyze these samples to compare genetic and protein differences. The goal is to better underst…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Oct 15, 2026 00:00 UTC
-
New study aims to outsmart hepatitis b drug resistance
Knowledge-focused Recruiting nowThis study looks at how the hepatitis B virus changes over time in people taking antiviral drugs. Researchers will analyze blood samples from 700 adults in Turkey to see if the virus becomes resistant to treatment. The goal is to help doctors choose the best medications for each …
Sponsor: Yaşar Bayındır, MD • Aim: Knowledge-focused
Last updated Oct 15, 2026 00:00 UTC
-
Safer syringe program aims to cut infections in drug users worldwide
Knowledge-focused Recruiting nowThis study looks at whether giving out special syringes with less leftover space (low dead-space) can help reduce the spread of HIV and hepatitis among people who inject drugs. Researchers will talk with participants and track their health in several countries. The goal is to fin…
Sponsor: Médecins du Monde • Aim: Knowledge-focused
Last updated Oct 11, 2026 00:00 UTC
-
Brain scans reveal secrets of lost smell
Knowledge-focused Recruiting nowThis study tracks 80 adults with different smell disorders (like total loss, partial loss, or distorted smell) plus healthy volunteers over one year. Researchers use brain scans, smell tests, and questionnaires to see how the brain changes and how smell loss impacts mood and dail…
Sponsor: National Institute on Deafness and Other Communication Disorders (NIDCD) • Aim: Knowledge-focused
Last updated Oct 11, 2026 00:00 UTC
-
Could a COVID shot boost cancer treatment? new study investigates
Knowledge-focused Recruiting nowThis study looks at whether getting an mRNA COVID-19 vaccine within three months before starting immunotherapy improves outcomes for people with liver cancer. Researchers will review medical records of 200 patients in Austria to compare response rates, survival, and side effects …
Sponsor: Medical University of Graz • Aim: Knowledge-focused
Last updated Oct 10, 2026 00:00 UTC
-
Liver biobank aims to unlock secrets of hepatitis and fatty liver disease
Knowledge-focused Recruiting nowResearchers at the State University of New York at Buffalo are creating a biorepository, a collection of blood and liver tissue samples, from people with and without liver diseases. The goal is to give future scientists high-quality specimens to study how conditions like hepatiti…
Sponsor: State University of New York at Buffalo • Aim: Knowledge-focused
Last updated Oct 10, 2026 00:00 UTC
-
HIV hiding spots revealed in treatment pause study
Knowledge-focused Recruiting nowThis study aims to understand where HIV hides in the body when people stop their daily antiretroviral therapy (ART) for a short time. Fifty adults with HIV will either stay on ART or pause it for up to 90 days. Researchers will use PET/CT scans and take small tissue samples from …
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Oct 10, 2026 00:00 UTC
-
HIV study aims to unlock mystery of Post-Treatment immune Flare-Ups
Knowledge-focused Recruiting nowThis study looks at why some people with HIV develop Immune Reconstitution Inflammatory Syndrome (IRIS) after starting HIV medications. Researchers will use PET scans and lymph node biopsies to track inflammation and immune recovery in 300 adults. The goal is to better understand…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Oct 10, 2026 00:00 UTC
-
Pandemic's hidden cost: breast cancer patients face financial strain
Knowledge-focused Recruiting nowThis study looks at how the COVID-19 pandemic impacted out-of-pocket costs, lost wages, and unemployment for 600 breast cancer patients undergoing surgery. Participants will fill out questionnaires about their financial experiences. The goal is to understand the financial toxicit…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Oct 09, 2026 00:00 UTC
-
Melanoma Patients' pandemic struggles under the microscope
Knowledge-focused Recruiting nowThis study uses a 10-minute questionnaire to learn how the COVID-19 pandemic impacted the quality of life, mental health, finances, and social connections of people with melanoma. Researchers will also look at what factors, like social support, helped people cope. About 1,152 par…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Oct 09, 2026 00:00 UTC
-
Massive study aims to unlock secrets of COVID-19 immunity
Knowledge-focused Recruiting nowThis study, run by the National Institute of Allergy and Infectious Diseases, collects blood and stool samples from up to 5,000 people of all ages who have or had COVID-19, as well as those heavily exposed but uninfected. Researchers will analyze immune responses and genetic fact…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Oct 09, 2026 00:00 UTC
-
What shields kids from flu? scientists track blood and nose immunity
Knowledge-focused Recruiting nowResearchers follow 150 healthy children aged 2 to 5 in South Africa through a flu season to see how immune responses in blood and the nose relate to protection against influenza. Nurses collect nasal swabs three times a week and blood samples before, during, and after the season.…
Sponsor: National Institute for Communicable Diseases, South Africa • Aim: Knowledge-focused
Last updated Oct 08, 2026 00:00 UTC
-
Fake news vaccine: study tests 'Prebunking' to shield young women from HIV drug myths
Knowledge-focused Recruiting nowThis study tests whether a short 'inoculation' message can help young women in South Africa resist misinformation about lenacapavir, a new twice-yearly injection for HIV prevention. 1,500 women aged 18-29 will be randomly assigned to receive either the inoculation message or unre…
Sponsor: University of Pennsylvania • Aim: Knowledge-focused
Last updated Oct 08, 2026 00:00 UTC
-
Where does COVID hide after recovery? new study aims to find out
Knowledge-focused Recruiting nowThis study follows about 800 people who have recovered from COVID-19 to learn how long the virus can stay in different parts of the body, such as the nose, stool, semen, and breast milk. Researchers will also track how the immune system responds and look for any long-term health …
Sponsor: Columbia University • Aim: Knowledge-focused
Last updated Oct 07, 2026 00:00 UTC
-
Hepatitis b: can a european data pool crack the code for a cure?
Knowledge-focused Recruiting nowResearchers across Europe are building a registry of people with hepatitis B to study how the virus behaves and how the immune system responds. The registry aims to collect health information from about 3,000 participants, including those with hepatitis B alone or with other infe…
Sponsor: Hannover Medical School • Aim: Knowledge-focused
Last updated Oct 07, 2026 00:00 UTC
-
Hunting the quiet phase of a Mosquito-Borne virus before the next outbreak
Knowledge-focused Recruiting nowRift Valley fever spreads from livestock such as cattle, sheep, goats, and camels to people, and East and Central Africa have seen more than 15 major epidemics in 50 years. Researchers are studying hotspots in Kenya, Uganda, Tanzania, and the Democratic Republic of Congo to measu…
Sponsor: Washington State University • Aim: Knowledge-focused
Last updated Oct 07, 2026 00:00 UTC
-
Breast cancer subtypes may hold clues to survival and cost
Knowledge-focused Recruiting nowResearchers in Bogota, Colombia, are reviewing the medical records of 370 women treated for breast cancer between 2014 and 2024. They want to see how different molecular subtypes of the disease relate to survival, recurrence, treatment response, and side effects. The study also l…
Sponsor: Fundación Santa Fe de Bogota • Aim: Knowledge-focused
Last updated Oct 04, 2026 00:00 UTC
-
Hidden threat: hepatitis d prevalence under the microscope
Knowledge-focused Recruiting nowThis study aims to find out how often people with chronic hepatitis B also have hepatitis D, and which types of the virus are most common. Researchers will interview about 2,400 participants and take blood samples to look for links with vaccination history, lifestyle, and other f…
Sponsor: Tam Anh Research Institute • Aim: Knowledge-focused
Last updated Oct 04, 2026 00:00 UTC
-
New study aims to make exercise safer for kids with cystic fibrosis, sickle cell, and long COVID
Knowledge-focused Recruiting nowThis study is working to create better exercise tests for children with cystic fibrosis, sickle cell disease, or long COVID. Current tests are designed for healthy athletes and may not be safe or useful for these kids. Researchers will track 240 children over 3-4 years, measuring…
Sponsor: University of California, Irvine • Aim: Knowledge-focused
Last updated Oct 04, 2026 00:00 UTC
-
Clearing hepatitis b may lift the weight of stigma, study asks
Knowledge-focused Recruiting nowResearchers are asking whether people who reach a functional cure for chronic hepatitis B feel less stigma and report better physical and mental health than those who are not cured or who relapse. The study enrolls about 400 adults from an existing hepatitis B cohort in China, so…
Sponsor: Zhiliang Gao • Aim: Knowledge-focused
Last updated Oct 04, 2026 00:00 UTC
-
HIV and aging in west africa: new study to uncover hidden frailty risks
Knowledge-focused Recruiting nowThis study will compare frailty and other age-related health problems in 600 older adults (60+) in Burkina Faso, Côte d'Ivoire, and Togo — half living with HIV, half without. Researchers will use surveys, medical checks, and interviews to understand how HIV affects aging and what…
Sponsor: ANRS, Emerging Infectious Diseases • Aim: Knowledge-focused
Last updated Oct 04, 2026 00:00 UTC
-
Massive liver study seeks 8,000 volunteers to unlock disease secrets
Knowledge-focused Recruiting nowThis study aims to learn more about liver diseases like hepatitis B, C, and D by observing up to 8,050 participants over time. Participants will have yearly check-ups, blood and urine tests, and liver ultrasounds. Some may be offered experimental treatments if they qualify. The g…
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Knowledge-focused
Last updated Oct 03, 2026 00:00 UTC
-
Hepatitis d study hunts for biomarkers to predict liver damage
Knowledge-focused Recruiting nowHepatitis D is the most severe form of viral hepatitis, often leading to liver failure and death. Researchers at Hannover Medical School are running a multicenter cohort study to screen blood and liver samples from 750 adults with hepatitis D for biomarkers linked to disease cont…
Sponsor: Hannover Medical School • Aim: Knowledge-focused
Last updated Oct 03, 2026 00:00 UTC
-
The viruses patients catch after they check in
Knowledge-focused Recruiting nowResearchers at four French hospitals are measuring how often patients and health care workers catch influenza, COVID-19, or RSV during a hospital stay. Anyone over 18 with fever, cough, or sore throat is offered a nose swab and a questionnaire about health, vaccination, and sympt…
Sponsor: Hospices Civils de Lyon • Aim: Knowledge-focused
Last updated Oct 03, 2026 00:00 UTC
-
Massive VA study tracks COVID-19 drug use in 400,000 veterans
Knowledge-focused Recruiting nowThis study reviews medical records from up to 400,000 U.S. Veterans to see how COVID-19 treatments like Paxlovid and remdesivir are used and how well they work. It also looks at RSV and flu patterns. The goal is to improve treatment strategies for respiratory viruses in the VA he…
Sponsor: VA Office of Research and Development • Aim: Knowledge-focused
Last updated Oct 02, 2026 00:00 UTC
-
Can a job workshop help black men with HIV stay healthy?
Knowledge-focused Recruiting nowThis study tests whether a two-day employment program can help young Black men who have sex with men stay engaged in HIV care. Researchers will ask 132 participants about their satisfaction and track changes in job-seeking confidence and sexual health visits over 13 months. The g…
Sponsor: University of Chicago • Aim: Knowledge-focused
Last updated Oct 02, 2026 00:00 UTC
-
Can a flu shot change a Doctor's judgment?
Knowledge-focused Recruiting nowResearchers want to know whether mild inflammation, like what happens after a flu shot, affects how healthcare providers make decisions about patients. The trial enrolls emergency medicine and internal medicine providers who receive either a seasonal influenza vaccine or a saline…
Phase 2 • Sponsor: University of Arkansas, Fayetteville • Aim: Knowledge-focused
Last updated Oct 02, 2026 00:00 UTC
-
Can a smartphone app boost hepatitis c care in the ER?
Knowledge-focused Recruiting nowThis study tests a smartphone app designed to teach emergency room patients about hepatitis C (HCV) and help them connect to follow-up care. Researchers will enroll 308 HCV-positive patients at an urban ER. The app provides personalized information on liver health and care option…
Sponsor: Johns Hopkins University • Aim: Knowledge-focused
Last updated Oct 01, 2026 00:00 UTC
-
Finger-Prick test aims to uncover hidden hepatitis c cases
Knowledge-focused Recruiting nowThis study is testing whether a quick finger-stick test can help find more people with hepatitis C and get them into treatment. About 60,000 adults at risk for hepatitis C will take the test at clinics, shelters, or prisons. The study itself does not provide treatment, but will c…
Sponsor: Kirby Institute • Aim: Knowledge-focused
Last updated Sep 30, 2026 00:00 UTC
-
Can saliva reveal the secrets of long COVID?
Knowledge-focused Recruiting nowThis study aims to understand why some people develop Long COVID—persistent symptoms after a COVID-19 infection—by tracking symptoms over time and analyzing saliva samples. Researchers will follow 500 adults aged 18 to 75 who have previously tested positive for SARS-CoV-2, collec…
Sponsor: University of North Carolina, Chapel Hill • Aim: Knowledge-focused
Last updated Sep 30, 2026 00:00 UTC
-
Scientists deliberately infect volunteers with dengue to unlock immune secrets
Knowledge-focused Recruiting nowThis study aims to understand how the human body responds to dengue virus infection, including in people who have had dengue before. Healthy volunteers aged 18 to 50 receive a single injection of a weakened dengue virus and are closely monitored for six months. Researchers measur…
Phase 1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Sep 27, 2026 00:00 UTC
-
Zambia study aims to unlock secrets of rotavirus vaccine failure
Knowledge-focused Recruiting nowThis study looks at why oral rotavirus vaccines are less effective in some low-income countries like Zambia. Researchers will collect blood, stool, and tissue samples from 43 adults to study how gut health and the immune system affect vaccine response. The goal is to find biologi…
Sponsor: Centre for Infectious Disease Research in Zambia • Aim: Knowledge-focused
Last updated Sep 27, 2026 00:00 UTC
-
Blood clues: why dengue turns deadly for some
Knowledge-focused Recruiting nowResearchers in Cambodia are studying blood samples from people hospitalized with dengue, influenza, or sepsis, plus healthy volunteers, to understand why dengue becomes severe in some patients. They collect clinical information and up to four blood samples per participant, then m…
Sponsor: Institut Pasteur du Cambodge • Aim: Knowledge-focused
Last updated Sep 25, 2026 00:00 UTC
-
Scientists launch Long-Term study to unravel rare spinal disease caused by a virus
Knowledge-focused Recruiting nowThis study follows people infected with HTLV-I virus, some of whom develop a rare spinal cord condition called HAM/TSP. Researchers will track changes in symptoms, immune system markers, and virus levels over time. The goal is to better understand why only a few infected people g…
Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) • Aim: Knowledge-focused
Last updated Sep 24, 2026 00:00 UTC
-
Healthy volunteers needed to help fight flu and zika
Knowledge-focused Recruiting nowThis study screens up to 5,000 healthy adults aged 18-65 to see if they can join future research on infectious diseases like flu and Zika. Volunteers undergo a 3-5 hour checkup including blood tests, heart exam, and chest X-ray. The goal is to build a pool of eligible participant…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Sep 24, 2026 00:00 UTC
-
Can better training help HIV patients beat depression?
Knowledge-focused Recruiting nowThis study compares two sets of strategies to help HIV clinics in Cape Town, South Africa, treat depression and improve medication adherence. Ten clinics will be randomly assigned to receive either basic support or enhanced training and supervision. Researchers will track how man…
Sponsor: University of Miami • Aim: Knowledge-focused
Last updated Sep 23, 2026 00:00 UTC
-
New 3D scanner could revolutionize how doctors measure kaposi sarcoma
Knowledge-focused Recruiting nowThis study will test a new 3D imaging device called SkinScan3D to see if it can measure Kaposi Sarcoma skin lesions more accurately and consistently than the current manual method. Researchers will compare the two methods in 300 adults with confirmed Kaposi Sarcoma who are starti…
Sponsor: Washington University School of Medicine • Aim: Knowledge-focused
Last updated Sep 23, 2026 00:00 UTC
-
HIV cure clue: does early treatment shrink the hidden virus?
Knowledge-focused Recruiting nowResearchers are comparing two groups of people living with HIV: those who began antiretroviral therapy during acute infection at least three years ago, and those who have been on treatment for more than 20 years. All participants have suppressed virus levels and uninterrupted tre…
Sponsor: University Hospital, Ghent • Aim: Knowledge-focused
Last updated Sep 23, 2026 00:00 UTC
-
Can you safely stop HIV PrEP shots? new study finds out
Knowledge-focused Recruiting nowThis study tests a program to help people safely stop taking long-acting injectable HIV prevention (PrEP). It will enroll 30 HIV-negative adults who are considering stopping or have stopped their PrEP shots. The program includes personalized coaching and, for some, monthly drug l…
Sponsor: Columbia University • Aim: Knowledge-focused
Last updated Sep 23, 2026 00:00 UTC
-
Scientists launch national study to track immune weakness linked to severe COVID
Knowledge-focused Recruiting nowThis study follows 500 adults in France who have either a genetic defect or autoantibodies that weaken their type I interferon immune response. Researchers will collect blood samples and health data over 1 to 4 years to track infections, autoimmune diseases, and cancers. The goal…
Sponsor: Institut National de la Santé Et de la Recherche Médicale, France • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
Scientists map HIV's hiding spots in early infection
Knowledge-focused Recruiting nowResearchers want to understand how HIV builds a hidden reservoir in the body when someone starts treatment during the earliest stage of infection. The study follows 70 recently infected people who begin combination antiretroviral therapy right away. Over two years, participants g…
Sponsor: University Hospital, Ghent • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Blood platelets may hold clues to HIV's hidden hideouts
Knowledge-focused Recruiting nowThis study investigates whether platelets—tiny blood cells involved in clotting—interact with HIV-infected immune cells in ways that affect the virus's ability to persist despite treatment. Researchers will collect blood samples from 90 adults with HIV who have had undetectable v…
Sponsor: Tourcoing Hospital • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Decades of HIV data could reveal which treatments last
Knowledge-focused Recruiting nowResearchers follow people with HIV who took part in earlier HIV-NAT studies to see how their health changes over many years. The study collects information on treatment history, side effects, other illnesses, and lab results such as viral load and CD4 counts. By tracking a large …
Sponsor: The HIV Netherlands Australia Thailand Research Collaboration • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Scientists hunt for hidden COVID remnants in long COVID patients
Knowledge-focused Recruiting nowThis study aims to find out whether people with long COVID still have inactive remnants of the SARS-CoV-2 virus in their bodies. Researchers will collect tissue samples from 12 adults who have recovered from COVID-19, some with long COVID symptoms and some without. The goal is to…
Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Researchers seek blood donors to advance infectious disease science
Knowledge-focused Recruiting nowThis study collects blood plasma and white blood cells from healthy volunteers and people with HIV using a procedure called apheresis. The samples are used for laboratory research on infectious diseases and immune function. Up to 3,000 participants aged 18 and older will be enrol…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Scientists hunt for clues to deadly Mosquito-Borne viruses
Knowledge-focused Recruiting nowResearchers are studying people in Réunion and Mayotte who seek care for dengue, chikungunya, or Zika to understand why some cases become severe. The study collects blood and urine samples and asks patients about their quality of life. By comparing clinical, demographic, and envi…
Sponsor: Centre Hospitalier Universitaire de la Réunion • Aim: Knowledge-focused
Last updated Sep 17, 2026 00:00 UTC
-
Stanford launches massive study to track oropharyngeal cancer over time
Knowledge-focused Recruiting nowThis study aims to learn more about oropharyngeal carcinoma, a type of throat cancer that can be linked to HPV. Researchers will collect blood samples from 1,000 patients before treatment and at six follow-up visits, and also gather tumor tissue when available. The goal is to bet…
Sponsor: Stanford University • Aim: Knowledge-focused
Last updated Sep 17, 2026 00:00 UTC
-
Scientists launch major study to track viruses in healthy and immunocompromised patients
Knowledge-focused Recruiting nowThis study aims to collect samples and medical information from people of all ages who have or have been exposed to viral infections, including COVID-19 and herpes. Researchers want to understand how viruses affect healthy individuals versus those with weakened immune systems. Pa…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Sep 16, 2026 00:00 UTC
-
Massive Real-World database aims to map how chronic diseases interact
Knowledge-focused Recruiting nowOPERA is a large observational database that collects health records from people treated for chronic conditions such as HIV, liver disease, inflammatory bowel disease, heart disease, rheumatic disease, and neurodegenerative disease. Researchers use the records to study how these …
Sponsor: Epividian • Aim: Knowledge-focused
Last updated Sep 13, 2026 00:00 UTC
-
HIV pain puzzle: are natural painkillers to blame?
Knowledge-focused Recruiting nowThis study looks at whether people with HIV have chronic pain because their bodies don't make enough natural painkillers (opioid peptides). Researchers will test pain sensitivity in 200 adults (with and without HIV) using heat, touch, and pressure. The goal is to understand the c…
Sponsor: Florida International University • Aim: Knowledge-focused
Last updated Sep 13, 2026 00:00 UTC
-
New study aims to unlock why infections hit mitochondrial disease patients hard
Knowledge-focused Recruiting nowThis study follows 400 people with mitochondrial disease and their household members to learn how infections affect them. Researchers will analyze blood samples and health records to find immune patterns linked to severe illness. The goal is to improve care and identify potential…
Sponsor: National Human Genome Research Institute (NHGRI) • Aim: Knowledge-focused
Last updated Sep 12, 2026 00:00 UTC
-
How does COVID-19 hit people born with weak immune systems?
Knowledge-focused Recruiting nowResearchers are running a worldwide survey to learn how COVID-19 affects children and adults who have primary immune deficiencies, a group of rare inherited conditions that weaken the immune system. Doctors enter health information about their patients who had confirmed or probab…
Sponsor: Imagine Institute • Aim: Knowledge-focused
Last updated Sep 12, 2026 00:00 UTC
-
Scientists probe Virus-Cancer link to unlock better treatments
Knowledge-focused Recruiting nowThis study looks at how viruses change the environment around tumors in people with lymphoma, lung cancer, or anal cancer. Researchers will analyze blood and tumor samples from 254 patients to understand why some cancers resist treatment. The goal is to find new ways to make anti…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Sep 12, 2026 00:00 UTC
-
Your smartwatch could spot the flu before you feel it
Knowledge-focused Recruiting nowThis study enrolls healthy adults who are already part of a respiratory virus challenge study at the NIH. Participants wear a smartwatch and use a smartphone to track temperature, heart rate, coughs, and other health signals. The goal is to see if these devices can detect subtle …
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Sep 11, 2026 00:00 UTC
-
Can a blood bank unlock the secrets of HIV control?
Knowledge-focused Recruiting nowThis observational study enrolls 2,500 people with HIV to build a detailed bank of blood samples and health records. Researchers will use these specimens to investigate how the virus behaves, why some people progress slowly or control the virus without medication, and how antiret…
Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated Sep 10, 2026 00:00 UTC
-
10,000 adults to be tracked for RSV – could pave way for vaccine decisions
Knowledge-focused Recruiting nowThis study will track 10,000 adults in Hong Kong with respiratory symptoms to measure how often RSV causes illness and how severe it gets. Researchers will collect nose and throat samples and blood tests over several weeks. The goal is to fill knowledge gaps about RSV in adults a…
Sponsor: Chinese University of Hong Kong • Aim: Knowledge-focused
Last updated Sep 03, 2026 00:00 UTC
-
Scientists launch major study to unravel mysteries of rare brain infection PML
Knowledge-focused Recruiting nowThis study follows 700 people with progressive multifocal leukoencephalopathy (PML), a rare brain infection caused by the JC virus. Researchers will collect blood, spinal fluid, and brain scans over time to understand how the disease progresses. No treatment is given; the goal is…
Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) • Aim: Knowledge-focused
Last updated Sep 02, 2026 00:00 UTC
-
Can surveillance catch birth defects early in HIV-Affected pregnancies?
Knowledge-focused Recruiting nowThis study sets up a monitoring program to track pregnancy outcomes and newborn health in HIV-positive and HIV-negative women at clinics in the IeDEA network. Researchers will watch for complications like miscarriage, preterm birth, and congenital abnormalities. The goal is to be…
Sponsor: Indiana University • Aim: Knowledge-focused
Last updated Aug 26, 2026 00:00 UTC
-
Can tracking thousands of patients unlock the secrets of rare EBV-driven blood cancers?
Knowledge-focused Recruiting nowThis study follows 1,500 people with Epstein-Barr virus-positive T/NK-cell lymphoproliferative diseases — rare conditions where the virus drives abnormal immune cell growth. Researchers will collect medical history, treatment details, and blood samples to see how the diseases beh…
Sponsor: Rong Tao • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
Dengue danger linked to leaky gut? new study investigates
Knowledge-focused Recruiting nowThis observational study will enroll 190 hospitalized adults with dengue in Bangladesh to see if a 'leaky gut' — where bacteria and toxins escape the intestines into the blood — is linked to severe disease. Researchers will measure gut leakage markers in blood, perform abdominal …
Sponsor: University of Oxford • Aim: Knowledge-focused
Last updated Aug 08, 2026 00:03 UTC
-
A crystal ball for ICU infections? new model aims to forecast who survives resistant bacteria
Knowledge-focused Recruiting nowThis study aims to develop a predictive model for mortality in critically ill patients who carry multidrug-resistant gram-negative bacteria (MDR-GNB). Researchers will follow about 1,500 adults in intensive care units (ICUs) who are colonized with these bacteria, tracking their i…
Sponsor: Fundacion SEIMC-GESIDA • Aim: Knowledge-focused
Last updated Aug 08, 2026 00:03 UTC
-
France launches massive virus surveillance in GP clinics
Knowledge-focused Recruiting nowThis study will track which respiratory viruses—like flu, COVID-19, and RSV—are circulating in French primary care clinics each winter. Up to 25,000 patients with cold or flu symptoms will provide a saliva or nose swab sample. The goal is to monitor virus activity and help guide …
Sponsor: Institut National de la Santé Et de la Recherche Médicale, France • Aim: Knowledge-focused
Last updated Aug 05, 2026 00:00 UTC
-
HIV and fatty liver: a hidden link under the microscope
Knowledge-focused Recruiting nowThis study follows 250 people newly diagnosed with HIV and 161 healthy volunteers over five years to see who develops metabolic fatty liver disease (MASLD). Researchers use annual blood tests, ultrasounds, and FibroScans to measure liver fat and stiffness. The goal is to uncover …
Sponsor: Yaşar Bayındır, MD • Aim: Knowledge-focused
Last updated Aug 01, 2026 00:00 UTC
-
Could centralized surgery boost ovarian cancer survival?
Knowledge-focused Recruiting nowThis study examines whether concentrating ovarian cancer surgery in specialized centers and changes in treatment during the COVID-19 pandemic affect how long patients live without their cancer returning. Researchers will follow about 200 women diagnosed with epithelial ovarian ca…
Sponsor: Azienda USL Reggio Emilia - IRCCS • Aim: Knowledge-focused
Last updated Jul 26, 2026 00:00 UTC
-
What happens to the immune system after COVID-19? a major study aims to find out.
Knowledge-focused Recruiting nowThis study follows 800 adults who have recovered from COVID-19 to understand how their immune systems respond over the long term. By collecting blood samples and health data, researchers hope to uncover why some people develop lingering symptoms, known as Long COVID. The goal is …
Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated Jul 25, 2026 00:00 UTC
-
Can a simple roadside test catch liver disease before it turns deadly?
Knowledge-focused Recruiting nowThis study aims to find undiagnosed cases of advanced liver fibrosis and viral hepatitis B and C in the general population of Seine Saint Denis, France. Using a combination of rapid diagnostic tests and a portable liver stiffness scanner (FibroScan), researchers will screen 600 a…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jul 25, 2026 00:00 UTC
-
13,000 volunteers shed light on who gets sick from COVID-19
Knowledge-focused Recruiting nowThis large observational study follows 13,000 UK adults to understand who gets COVID-19, how the disease progresses, and its long-term effects on physical and mental health. Researchers track risk factors, symptoms, and outcomes like hospitalization. The data may also serve as a …
Sponsor: Queen Mary University of London • Aim: Knowledge-focused
Last updated Jul 19, 2026 00:00 UTC
-
Hormones may change how HIV prevention drug works in the body
Knowledge-focused Recruiting nowThis study looks at how natural hormones and hormone therapy (like birth control or gender-affirming hormones) affect the way the HIV prevention drug cabotegravir works in the body. Researchers will measure drug levels in blood, tissues, and fluids in 32 HIV-negative adults. The …
Phase 1 • Sponsor: Johns Hopkins University • Aim: Knowledge-focused
Last updated Jul 15, 2026 00:00 UTC
-
Immune clues in severe RSV: what makes some babies sicker?
Knowledge-focused Recruiting nowThis study looks at the immune system's response in infants aged 6 months or younger who are hospitalized with RSV bronchiolitis. Researchers will collect nasal swabs and blood samples to measure immune markers like interferons and cytokines. The goal is to understand why some ba…
Sponsor: Centre Hospitalier Intercommunal Creteil • Aim: Knowledge-focused
Last updated Jul 15, 2026 00:00 UTC
-
Scientists hunt for hidden ARDS subtypes to crack deadly lung failure
Knowledge-focused Recruiting nowThis study will analyze samples from 130 ICU patients with ARDS (a severe lung injury) to better understand why the condition varies so much between people. Researchers will examine lung fluid, blood, and CT scans to identify distinct biological subtypes. The goal is not to test …
Sponsor: Medical University of Vienna • Aim: Knowledge-focused
Last updated Jul 12, 2026 00:00 UTC
-
COVID-19's skin secrets: could chilblains hold clues to the virus?
Knowledge-focused Recruiting nowThis study looks at skin problems that appear during a COVID-19 infection, with a special focus on chilblains (painful red or purple bumps on fingers or toes). Researchers want to understand why these skin changes happen—whether from the virus itself, tiny blood clots, or inflamm…
Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
French study to reveal true COVID-19 infection rates during lockdown easing
Knowledge-focused Recruiting nowThis study is following 1,000 people in the Alpes-Maritimes region of France to see how many were infected with the coronavirus during the deconfinement period. Researchers are using blood tests to measure immune responses and will also look at how air pollution might affect the …
Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Austrian study seeks to eliminate hepatitis by linking patients to care
Knowledge-focused Recruiting nowThis study in South-East Austria looks at past lab results to find people with hepatitis B, C, or D who may not know they have it. Researchers will invite these individuals to a clinic to discuss treatment options. The goal is to connect them to care and track how many get cured,…
Sponsor: Vanessa Stadlbauer-Koellner, MD • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
RSV in infants: new study aims to unlock asthma mystery
Knowledge-focused Recruiting nowThis study follows 300 infants to understand how catching RSV very early (before 4 months old) versus later (after 6-9 months) affects their immune system and long-term health. Researchers will measure antibody responses and track asthma-like symptoms. The goal is to learn why ea…
Sponsor: University of British Columbia • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Could a simple antibody test predict severe COVID-19?
Knowledge-focused Recruiting nowThis study aims to find out how common anti-annexin A2 antibodies are in people hospitalized with COVID-19 and whether these antibodies are linked to lung damage or blood clots. Researchers will test blood samples from 300 adult patients at one hospital. The goal is to see if the…
Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Transplant patients at risk of Drug-Resistant virus under microscope
Knowledge-focused Recruiting nowThis study is looking at 100 adult patients who have had an organ or stem cell transplant and later developed a CMV infection that is resistant or hard to treat with standard antiviral drugs. Researchers want to find out how common this problem is and what factors make it more li…
Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Scientists investigate why some people suffer severe COVID-19
Knowledge-focused Recruiting nowThis study looks at why some people had severe COVID-19 while others had mild symptoms. Researchers will compare the immune system's early response (called interferon) in 134 adults who were sick during the first wave. They also want to see if gut bacteria play a role. The goal i…
Sponsor: Hospices Civils de Lyon • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC
-
Worldwide HIV watch: 2,500 volunteers join Long-Term infection study
Knowledge-focused Recruiting nowThis observational study will follow 2,500 people aged 14–55 who are at risk for HIV across multiple countries. Researchers will track how many new HIV and other sexually transmitted infections occur over time. The goal is to gather data that could help design future studies aime…
Sponsor: Henry M. Jackson Foundation for the Advancement of Military Medicine • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:39 UTC
-
Letting go of grudges might help HIV patients live better
Knowledge-focused Recruiting nowThis study looks at whether being more forgiving and holding less resentment can improve quality of life for people living with HIV. Researchers will follow 206 participants at a French hospital, measuring their tendency to forgive and their well-being. The goal is to see if forg…
Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:39 UTC
-
Scientists investigate Africa's COVID-19 mystery: why were cases so mild?
Knowledge-focused Recruiting nowThis study in Malawi aims to understand why COVID-19 was much less severe there than in Europe and the Americas. Researchers will follow 1500 people, including those infected and their household contacts, to see how factors like prior infections, nutrition, and immune responses a…
Sponsor: Boston University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:39 UTC
-
Zambia launches massive study to uncover why some HIV patients still get very sick
Knowledge-focused Recruiting nowThis study in Zambia will follow about 11,800 people with advanced HIV who are starting or restarting antiretroviral therapy (ART). Researchers want to learn who these patients are, what challenges they face, and how well they do in the first six months of treatment. The goal is …
Sponsor: Boston University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC
-
3500 hepatitis b patients needed to hunt for cure biomarker
Knowledge-focused Recruiting nowThis study is creating a large collection of blood samples and health data from 3500 people with hepatitis B, including those who have already cleared the virus. Researchers will use these samples to look for viral RNA patterns that could signal a functional cure. No new treatmen…
Sponsor: Hospices Civils de Lyon • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC
-
Massive brazilian registry aims to uncover hidden health risks in HIV patients
Knowledge-focused Recruiting nowThis study is creating a large database of health information from 743 adults with HIV/AIDS across Brazil. Researchers will look at how common chronic diseases like heart disease, kidney disease, and cancer are in this group. The goal is to gather data to help improve health poli…
Sponsor: Hospital Alemão Oswaldo Cruz • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC
-
New study aims to catch transplant complications early with blood and urine tests
Knowledge-focused Recruiting nowThis study is looking at 1,000 liver transplant recipients to see if testing their blood, urine, and tissue samples can detect early signs of chronic kidney disease, acute rejection, or hepatitis C. The goal is to find simple biomarkers that could lead to earlier treatment and fe…
Sponsor: Northwestern University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
AI reads your symptom stories to find hidden medical clues
Knowledge-focused Recruiting nowThis study collects anonymous symptom descriptions from 1,000 adults through an online platform. An AI tool then searches medical literature to see if it can find reliable biological signals in the free-text descriptions. The goal is to test how accurate and consistent the AI's f…
Sponsor: OpenGenome • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:35 UTC
-
10,000 australians with hepatitis b to be tracked in landmark real-world study
Knowledge-focused Recruiting nowThis study will follow 10,000 people in Australia who have chronic hepatitis B to see how well they are connected to care and treatment. Researchers will collect information from clinics across the country to understand who is getting treated and what their health needs are. No n…
Sponsor: Kirby Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:35 UTC